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Endoplasmic reticulum stress and the unfolded protein response are implicated in a 
number of diseases, from cancer to ankylosing spondylitis. Understanding the 
mechanisms underlying this response and how these may differ between cell types 
is important in beginning to address potential pharmacological therapies. This thesis 
investigated the effect of the pharmacological endoplasmic reticulum stress inducer 
tunicamycin, and the isoflavine tyrosine kinase inhibitor genistein on the 
downstream pathways of the subsequent unfolded protein response. This was 
investigated in the two human cell lines HeLa and HT1080.  
The investigations in this thesis found that tunicamycin induced differential 
activation of downstream unfolded protein response pathways in the two cell lines. 
The first main finding was that the HT1080 cells exhibited chronic activation of stress 
related phosphorylation pathways in comparison to the more transient response of 
the HeLa cells. Both cell lines showed a peak expression of the pro-survival proteins 
after 10 minutes of tunicamycin treatment, as well as showing longer-term responses 
to stress with later induction of the phosphorylated-Stat3 protein. This indicates that 
both acute and chronic effects of ER stress occur in both cell types, but that HT1080 
cells had a more consistent expression of stress related proteins. From live cell 
imaging data, HeLa cells were much more sensitive to tunicamycin induced motility 
inhibition than the HT1080 cells, which may reflect a state of resistance to stress-
induced changes in motility in the HT1080 cells. Genistein decreased the 
phosphorylation of stress related phosphoproteins slightly.  
These findings reveal that consideration of the cell type must be made when devising 
pharmacological routes to address conditions where endoplasmic reticulum stress is 
a pathological factor. The differential response of cell lines to pharmacologically 
induced ER stress could be exploited to create selective therapies specific to 
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1.1 Endoplasmic reticulum stress in context 
Endoplasmic reticulum stress (ER stress) is a complex series of reactions that cells 
undergo when subjected to the specific stress stimulus of misfolded proteins. This 
introduction will outline the various factors involved in ER stress; from the pathways 
activated to some diseases involved, and will also outline the rationale of the 
experiments conducted for this project along with providing information about 
exactly what the different pharmacological stress inducers do.  
ER stress is involved in a plethora of diseases including type II diabetes (Back and 
Kaufman, 2012), cancer (Urra et al., 2016) and neurodegenerative diseases (Lindholm 
et al., 2006). ER stress occurs when misfolded proteins accumulate in the ER. 
Misfolded proteins may arise due to a number of reasons, such as mutations, 
overloading of protein folding capacity and also due to pharmacological induction 
using drugs to induce general or specific protein misfolding. Misfolding can 
contribute to diseases such as AS, and may be a factor affecting disease progression 
in other diseases such as cancer due to the augmenting effect of ER stress on 
tumorigenesis, which will be later discussed. The presence of misfolded proteins in 
the ER activates a cellular stress response called the unfolded protein response or 
UPR.  
Three specific and different pathways are activated in the cell during the UPR (Wang 
and Kaufman, 2014), and these IRE1α, ATF6α and PERK pathways determine the 
outcome of a stress response for the cell. These pathways will be discussed 
molecularly in the following sections. The outcome is either apoptosis or resolution 
of ER stress through an increase in folding capacity, decreased protein transport and 
decreased protein synthesis. ERAD (endoplasmic reticulum associated degradation) 
is increased with the activation of the UPR and this is when the misfolded proteins in 
the ER are targeted for ubiquitination and degradation. ER stress has attracted 
attention for the development of new therapies for a range of diseases. For example, 
if ER stress can be modulated, or if different cell types behave differently under ER 
stress, then there are implications for creating specific therapies that could target ER 
stress in selective cells. As the diseases involving ER stress affect a wide range of 
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bodily functions and areas, it is important to question whether the effects seen in 
one group of cells will be the same in another cell type, and if differences are seen, 
then perhaps this could unlock potential areas of investigation to establish why those 
differences exist, which could in turn reveal potential therapeutic targets.  
1.2 Protein Folding 
Protein folding is an essential process within the cell, and is closely linked to 
activation of ER stress and the UPR. Proteins need to be folded into a three-
dimensional shape. The protein begins as a random coil and sequence of amino acids, 
which interact with each other to form covalent bonds that are the basis for a 
protein’s 3D structure. The sequence of amino acids is the primary determinant for 
its ultimate 3D functional structure (Anfinsen, 1972), but the exact process of how 
the protein folds is affected by multiple factors. One of the main driving forces behind 
the folding is related to the hydrophobic nature of specific amino acids such as 
alanine, isoleucine, leucine, phenylalanine, valine, proline and glycine. In a solvent, 
the hydrophobic amino acids are repelled by the solvent and therefore a hydrophobic 
protein core is created, with this core being shielded from the solvent by non-
hydrophobic, polar amino acids. These polar amino acids include glutamine, 
asparagine, histidine, serine, threonine, cysteine, methionine, tryptophan. The 
process is much more complex than just this though and as the Levinthal paradox 
demonstrates (Zwanzig et al., 1992), a protein left to fold without any external factors 
would take a vast amount of time, too long to be biologically viable, due to the huge 
number of possible folding conformations for the proteins. Kinetics therefore is 
important for folding, with a bias against locally unfavourable conformations  which 
dramatically reduce the time taken to fold (Zwanzig et al., 1992). 
While proteins can fold by themselves, often co-translationally (Fedorov and 
Baldwin, 1997), an aid to folding often comes in the form of a group of proteins within 
the cell called chaperones. As the nascent intermediate structures are produced by 
the ribosome, the chaperones may come to assist the folding as well as helping fold 
the full length product after release (Fedorov and Baldwin, 1997). Many chaperones 
reside in the ER as a large amount of protein synthesis occurs here. The chaperones 
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may aid primarily in protein folding, but others help prevent aggregation of proteins 
by binding to their intermediate states. These two types of chaperones are classed 
‘holdases’ and ‘foldases’ (Hoffmann et al., 2004) and help maintain homeostasis in 
the cell, particularly under times of stress where the need for protein quality control 
is increased. Under conditions of cellular stress such as elevated temperature or 
denaturing conditions, chaperones are recruited to help alleviate this stress. Many 
chaperones are in fact heat shock proteins (HSPs), which primarily act under stressed 
conditions due to increased temperature for example acting as a protein denaturant. 
A key protein heavily implicated in ER stress specifically is the HSP70 chaperone, 
GRP78/BiP (Lee, 2005). This is an ER resident general chaperone, and has multiple 
functions in both the translocation machinery and maintaining the newly synthesised 
ER proteins in a stable state for translocation. Once bound to a substrate, BiP is able 
to aid in protein folding and aggregate prevention. Aggregate prevention is achieved 
through the combined work of HSP-70 chaperones and their co-chaperones; the J-
domain proteins (JDP). The chaperones bind to the hydrophobic regions of the non-
native proteins which prevents intermolecular interactions (demonstrating ‘holdase’ 
activity) (Mayer and Bukau, 2005). It is also a key component of the unfolded protein 
response, functioning in the signal transduction for the three pathways involved in 
the UPR.  
ER stress is a term referring to an accumulation of unfolded or misfolded proteins in 
the ER. The ER has a delicate homeostatic balance between protein load and protein 
folding capacity (Oslowski and Urano, 2011), and this can be disturbed via 
pathological and physiological insults which can result in the unfolded and misfolded 
proteins collecting in the ER and putting pressure on the cell’s folding apparatus. 
Unfolded proteins individually do not pose a strong threat to the cell, however when 
the unfolded proteins start to aggregate, this can have a cytotoxic effect on the cell 
so it is essential to clear up the potential threat of unfolded proteins to prevent 
cytotoxicity and to maintain proper functioning of the ER. The cytotoxicity of the 
aggregates stems from the excess activation of the ER stress response, and the push 
towards apoptosis when the stress is unresolvable (Uchio et al., 2007).  
1.3 Unfolded Protein Response 
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The UPR is activated when misfolded and unfolded proteins are present in the ER 
lumen. There are three signalling pathways in this stress response, all activated 
through the same first step – sequestration of BiP by unfolded proteins present in 
the ER. BiP has multiple roles, one of which is maintaining the three transmembrane 
receptor proteins for each branch of the UPR in an inactive state. When unfolded 
proteins begin accumulating in the ER, BiP is required for binding to help prevent 
aggregation and aid in re-folding, and as the free BiP supplies decrease, the BiP bound 
to the transmembrane receptors dissociates to meet the BiP demand and this 
subsequently allows activation of the different UPR branches (Wang and Kaufman, 
2014). The three pathways start with their respective transmembrane ER sensor 
proteins: IRE1α, ATF6α and PERK (Wang and Kaufman, 2014). These pathways 
resolve ER stress through increased folding capacity, increased protein transport out 
of the ER and increasing the activation of ER associated protein degradation, while 
preventing further protein synthesis – the adaptive response. If, however, the 
unfolded protein load exceeds the capacity of the unfolded protein response, then 
the cells undergo apoptosis (Wang and Kaufman, 2014). The pathways have many 
downstream signalling cascades (Wang and Kaufman, 2014) - for example IRE1α 
works via multiple different pathways including JNK signalling, XBP-1 splicing and 
regulated IRE1 dependent decay, so each branch of the UPR can be regulated 
individually. Cell fate determination is an important aspect of the UPR, and the 
balance between the three different pathways is central to deciding whether the cell 
undergoes apoptosis or survives. If the balance between survival and apoptosis is 
uneven, then it may lead to diseases such as cancer, and this will be explored in depth 
later. Over-active apoptosis, for example, could lead to degenerative diseases such 
as Parkinson’s or Alzheimer’s (Chen and Brandizzi, 2013). Chronic UPR activation is 
also closely linked with inflammation via phosphorylation of initiation factor 2 (eIF2α) 
by PERK; a translation initiation factor 2 kinase (eIF2α kinase) (Hotamisligil, 2010). 
This phosphorylation leads to translational suppression of inhibitory kappa B (IκB) , 
which acts as an inhibitor to the pro-inflammatory nuclear factor kappa B (NF-κB). 





The IRE1α branch of the UPR is a mammalian pro-survival pathway, but can also 
cause apoptosis due to the decay of anti-apoptotic micro-mRNAs (Upton et al., 2012). 
The IRE1α protein has a diverse downstream signalling cascade with two specific 
pathways contributing towards a decision of cell fate (Chen and Brandizzi, 2013). 
These pathways consist of unconventional splicing of the transcription factor, x-box 
binding protein 1 (Xbp-1) and regulated IRE1 dependent decay (RIDD).  
Originally it was believed that IRE1α signalling was terminated during chronic ER 
stress to facilitate apoptosis (Hetz, 2012), however it is now debated that IRE1α is 
persistently involved in UPR signalling and determines cell fate. After BiP dissociates 
from the IRE1α transmembrane protein, the protein’s luminal domain 
homodimerises, which consequently allows autophosphorylation of the cytoplasmic 
domains due to close proximity (Ali et al., 2011). The phosphorylation site lies within 
the central ~10 residues of the kinase segment (720-729), and the putative 
phosphorylation site is on Ser724. This activates the cytosolic RNase domain which 
carries out the splicing activity on Xbp-1 mRNA. By removing a 26 nucleotide intron 
from the mRNA, the codon reading frame is shifted and this results in the generation 
of a new COOH-terminal end that is a potent transactivation domain (Hetz et al., 
2011). The spliced XBP-1 (sXBP-1) can now activate multiple ER quality control and 
ER stress genes to help the cell adapt to the stress. Downstream effects of the spliced 
XBP-1 include upregulation of ER chaperones and ERAD associated genes (Yoshida et 
al., 2001) including ER resident chaperone genes such as heat shock protein/ 
chaperone DnaJ (Hsp40/DnaJ), ER Degradation Enhancing α-Mannosidase-like 
protein (EDEM) and HEDJ (Lee et al., 2003). XBP-1 has a well-documented role in the 
UPR, and curiously one study purports that the unspliced form may negatively 
regulate autophagy (Vidal and Hetz, 2013). An alternate pathway to XBP-1 splicing is 
RIDD, which represses adaptive responses and activates apoptosis (Chen and 
Brandizzi, 2013) due to IRE1α RNase cleaving multiple other mRNAs as well as XBP-1 
(Wang and Kaufman, 2014). These cleaved mRNAs include many ER localised mRNAs 
encoding secretory cargo proteins and proteins that promote folding (Han et al., 
2009). RIDD is also active during the switch between adaption and apoptosis and 
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during this transition phase, it degrades selective UPR target genes, one of which is 
BiP, ultimately increasing the ER stress intensity further shifting the balance towards 
apoptosis. Once a stress intensity threshold is reached, the RIDD degrades anti 
apoptotic micro-RNAs to induce apoptosis (Upton et al., 2012). These micro-RNAs 
function as repressors of the translation of Caspase-2 miRNA. Caspase-2 is a protease 
that plays an essential role in apoptosis (Vakifahmetoglu-Norberg and Zhivotovsky, 
2010). Through inhibiting anti Caspase-2 miRNA, Caspase 2 is upregulated through 
IRE1α activation, driving the cell towards apoptosis. This demonstrates how IRE1α 
acts a molecular switch, able to determine whether the cell undergoes apoptosis, or 
whether it adapts to the stress. 
The cell fate determination through the IRE1α pathway is further affected through 
cJUN NH2-terminal kinases (JNKs) during ER stress (Chen and Brandizzi, 2013). The 
mitogen protein kinase JNK and apoptosis signal regulating kinase 1 (ASK1) form a 
regulatory part of the IRE1α pathway. JNK along with RIDD, promotes apoptosis in 
the cell and therefore also plays a role in cell fate determination. ASK1 activates 
multiple downstream targets including MAPKs and JNK (HAYAKAWA et al., 2012). JNK 
phosphorylates and activates transcription factors such as cJUN and ATF2 to regulate 
gene expression levels while also regulating the stability of mRNA (Urano et al., 
2000). This pathway works via binding of TNF receptor-associated factor 2 (TRAF2) 
to the activated IRE1α which recruits ASK1 and JNK. This in turn activates BCL-2 
interacting mediator of cell death (BIM) and inactivates BCL-2 (Wang and Kaufman, 
2014). BIM is an important pro-apoptotic protein (Gogada et al., 2012) which induces 
the oligomerisation of the pro-aptotic Bax/Bak on mitochondria (BCL2 associated X, 
apoptosis regulator). Bax increases the opening of the mitochondrial voltage 
dependent anion channel, resulting in a loss of membrane potential and a release of 
cytochrome C. BCL-2 is an anti-apoptotic protein and the inactivation of this protein, 
coupled with the activation of BIM comprises the pro-apoptotic action of ASK1 and 
JNK recruitment. Figure 1.1 highlights the three possible routes that the IRE1α 




Figure 1.1: The IRE1α pathway can direct cell fate determination. 
The transmembrane receptor IRE1α homodimerises and autophosphorylates after 
dissociation of BiP due to sequestration from unfolded proteins. This may result in XBP1 




The next UPR pathway to consider is the ATF6α pathway, and this is activated slightly 
differently to IRE1α. Instead of autophosphorylation once BiP has dissociated, ATF6α 
translocates from the ER compartment to the golgi apparatus where it is cleaved 
from a full length protein (90 kDa), releasing a cytosolic fragment (50 kDa) (Zhang 
and Kaufman, 2004). This process is called regulated intermembrane proteolysis and 
it is a highly conserved process, whereby information is transferred to the nucleus 
from the ER in the form of a functionally active protein fragment. There are two steps 




ge of the protein substrate in the extra-cytoplasmic domain, and the second cleavage 
occurs in the membrane spanning domain (Rawson, 2002). The cytosolic fragment 
then migrates to the nucleus where it acts as a transcription factor, inducing ER stress 
genes including the transcriptional induction of XBP-1 (Galindo et al., 2012). 
Currently, ATF6 is only linked to the adaptive outcome of the UPR and no evidence 
yet suggests a link between ATF6 signalling and apoptosis. 
1.6 PERK 
The third branch of the UPR is PERK and this protein is activated in the same fashion 
as IRE1α. Once BiP disassociates, PERK homodimerises and autophosphorylates (Liu 
et al., 2000). PERK activates eIF2α via phosphorylation at S51, which attenuates 
translation initiation through regulation of the translational activity of eIF2. eIF2 
creates a ternary complex with GTP and the tRNAmet which is the initiator. This 
complex binds the 40S ribosomal subunit to make a 43S subunit – the preinitiation 
complex. This binds to the 5’ end of mRNA to scan downstream, and once a start 
codon (AUG) is found, tRNAmet binds to the codon, and the GTPase activating protein 
- eIF5 activates eIF2 hydrolysis of GTP. This results in the release of the eIF2 complex 
from the ribosome. Translation may then commence after the 60S subunit is 
recruited and the 80S initiation complex is formed. For a new round of translation 
initiation to begin, the GDP in eIF2 must be exchanged for GTP, which is achieved 
with the guanine nucleotide exchange factor eIF2B – a step that is inhibited by eIF5 
(Wang and Kaufman, 2014). The eIF2α is part of a heterotrimer that makes up eIF2 
along with a beta and a gamma subunit. The phosphorylated eIF2α increases the 
affinity of eIF2 for GDP greatly and this inhibits the GDP to GTP exchange with eIF2B, 
instead forming an inactive complex with eIF2 and sequestered eIF2B. There is a low 
ratio of eIF2B to eIF2, and this means that even small amounts of eIF2α 
phosphorylation can halt protein synthesis (Harding et al., 2000). Figure 1.2 shows a 





Figure 1.2: PERK activation results in general translational attenuation, but  selective pro-
apoptotic or pro-survival translation. 
Activated PERK phosphorylates eIF2α, preventing eIF2B from initiating translation via 
exchanging GDP for GTP. This is due to the greatly increased binding affinity of GDP when 
eIF2α is phosphorylated, so eIF2B is sequestered instead, forming an inactive complex with 
eIF2. This attenuates translation but selectively translates the mRNA for the transcription 
factor ATF4 which aids the adaptive UPR. ATF4 in turn transcribes CHOP which is a pro-
apoptotic transcription factor.  
 
While the phosphorylation of eIF2α results in a decrease of global mRNA translation, 
a paradoxical increase in ATF4 mRNA translation amongst other select mRNAs is 
observed due to selective translation (Harding et al., 2000). ATF4 is a transcription 
factor that enters the nucleus and upregulates ER stress genes. One target of ATF4 is 
activating the transcription of the growth arrest and DNA damage inducible protein 
34 (GADD34), which in turn promotes de-phosphorylation of eIF2α resulting in 
restored global translation. The other important transcription target of ATF4 is C/EBP 
homologous protein (CHOP), which has an important role in promoting apoptosis. 
CHOP has a similar function to ASK1/JNK in that it can upregulate the pro-apoptotic 
transcription of BIM (Puthalakath et al., 2007) as well as inhibiting anti-apoptotic BCL-
2 expression (McCullough et al., 2001). On top of this, BAX translocation to the 
mitochondria is promoted by CHOP (Szegezdi et al., 2006). As well as CHOP mediated 
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apoptosis, eIF2α phosphorylation from PERK in chronic stress also leads to apoptosis 
due to the attenuation of the two other UPR branches (Rutkowski et al., 2006). To 
induce apoptosis, a strong chronic activation of PERK is required, namely because of 
the short half-lives of ATF4 and CHOP (Rutkowski et al., 2006). It is possible that CHOP 
and ATF4 do not directly induce apoptosis, but instead work through indirect routes. 
This is supported by chromatin immunoprecipitation of ATF4 and CHOP, which 
selectively enriches sequences of DNA bound to target proteins, and sequencing of 
genes directly regulated by these two proteins (Han et al., 2013). This study 
discovered that there was no enrichment of target genes involved in cell death, by 
either CHOP or ATF4, when cells were under ER stress. Instead, it was found that 
CHOP and ATF4 interact and form heterodimers which upregulate protein synthesis 
and UPR genes. The expression of ATF4 and CHOP increases protein synthesis and 
consequently protein folding, which can lead to increased reactive oxygen species 
(ROS) creating oxidative stress and cell death. This data shows that the pro-apoptotic 
action of these two proteins is not direct, but works instead through increased 
protein synthesis, with resultant oxidative stress pushing the system towards an 
apoptotic outcome. The transient phosphorylation of eIF2α after stress halts protein 
synthesis and the subsequent induction of ATF4 and CHOP acts to restore this 
synthesis. However, if the protein folding homeostasis is not also restored by this 
point, then the resulting ROS production will drive the cells to apoptosis (Han et al., 
2013). This explains how the PERK pathway and the IRE1α pathway act as molecular 
switches to help cell fate determination through selective apoptosis of stressed cells. 
ATF4 also aids in withstanding oxidative stress by interacting with Nuclear factor-like 
2 (Nrf2) whose target genes encode antioxidant enzymes such as heme oxygenase-1 
(HO-1) and NAD(P)H:quinone oxidoreductase (NQO) which help limit toxicity and 
further induction of stress (He et al., 2001); however it does not prevent stress from 
occurring altogether (Clarke et al., 2014). In addition to these antioxidants, the 
dissociation of the Nrf2/Keap1 complex and activation of Nrf2 by PERK helps alleviate 
oxidative stress due to Nrf2’s function in maintaining glutathione levels, which 
functions as a buffer against rising ROS levels (Cullinan and Diehl, 2004). 
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The ER has a delicate redox balance, changes to which can severely perturb protein 
folding. The ER lumen is particularly sensitive to changes in the redox balance as 
disulphide bonds form through oxidative protein folding, which is dependent on the 
redox state of the cell. Under ER stress, the breakage and formation of disulphide 
bonds may produce ROS which can lead to oxidative stress (Cao and Kaufman, 2014). 
As well as this, ER stress can lead to mitochondrial dis-function which can result in an 
increase of mitochondrial ROS too, contributing further to oxidative stress. There is 
an interaction between ER stress and oxidative stress that acts as a positive feed-
forward loop, resulting in pro-apoptotic signalling and disrupted cell function (Cao 
and Kaufman, 2014). 
1.7 ER Stress in Disease 
1.7.1 Cancer 
ER stress is prevalent in many diseases and this provides a strong reason to continue 
research on the area. Cancer in particular has had a lot of research undertaken in the 
context of ER stress and how it affects tumorigenesis. In cancer, it is common for the 
tumour cores to become hypoxic (starved of oxygen) and consequently the 
availability of ATP is decreased. This in turn compromises the protein folding ability 
of the cells in the hypoxic core and thus the UPR is activated (Clarke et al., 2014). 
Multiple factors of the UPR make a difference to cancer prognosis and tumour 
progression, with the IRE1α and PERK pathways specifically contributing to 
tumorigenesis. Splicing of XBP-1 increases the resistance of tumour cells to hypoxia 
in hypoxic tumours. In XBP-1 deficient cells there was increased apoptosis in hypoxic 
conditions, and although a different system to tumour cells, this could indicate that 
XBP-1 splicing leads to a poorer prognosis in tumours (Romero-Ramirez et al., 2004). 
While XPB-1 knockout cells are not in the same system as tumour cells, there is 
evidently a link between this component of the UPR signalling pathways and tumour 
progression. 
PERK and IRE1α both have roles in promoting tumour angiogenesis and 
vascularisation is essential for tumour survival when hypoxia is an issue. Vascular 
endothelial growth factor, which helps promote angiogenesis, is upregulated by the 
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PERK-ATF4 branch of the UPR, and proangiogenic transcripts are upregulated in a 
PERK dependent manner (Blais et al., 2006). PERK also downregulates angiogenic 
inhibitors during glucose deprivation, and when PERK expression was silenced, the 
induction of angiogenesis mediators was considerably decreased, resulting in slower 
tumour growth (Wang et al., 2012). Due to the dual-action nature of the UPR 
pathways, both pro-apoptotic and anti-apoptotic, the role of IRE1α and PERK 
signalling is not always as clear-cut. PERK deletion has an effect on oxidative stress 
also; PERK deficient cells have an increased ROS production as well as a decrease in 
Nrf2 (Bobrovnikova-Marjon et al., 2010). Nrf2 was identified as a substrate for PERK, 
and it is a transcription factor whose protein products mediate redox level, including 
phase II detoxifying enzymes which promote survival under the oxidative stress 
conditions produced as a side effect of UPR activation (Cullinan et al., 2003). The 
protective function of PERK against oxidative stress further strengthens the idea that 
PERK is pro-tumorigenic; however, long term knockout can contribute to tumour 
susceptibility due to genomic instability (Bobrovnikova-Marjon et al., 2010). Tumour 
suppressive roles of CHOP have also been proposed, which is seemingly paradoxical 
considering the pro-tumour activity of the PERK pathway. In a mouse model of K-ras 
(G12V)-induced lung cancer, CHOP deletion appeared to significantly increase 
tumour incidence (Huber et al., 2013), illustrating that there is a dichotomy within 
the PERK pathway on which way it may affect tumorigenesis. 
The role of the PERK-ATF4 arm in tumour progression is evidently a complex one and 
there is a clear link between this branch of the UPR and tumorigenesis. The IRE1α 
arm also has a role to play, being involved in the upregulation of angiogenic factors 
and the downregulation of angiogenic inhibitors. Under-expressing IRE1α in a human 
glioma model, a mouse orthotopic brain model and a chick chorio-allantoic 
membrane assay demonstrated reduced tumour growth, angiogenesis and 
invasiveness, as expected (Auf et al., 2010).  
The IRE1α pathway has a role in plasma cell differentiation, due to the selective and 
specific requirement of XBP-1 in terminal differentiation of B cell lymphocytes into 
plasma cells (Reimold et al., 2001), and consequently, the IRE1α pathway has been 
the subject of in depth research in relation to multiple myeloma – a cancer of plasma 
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cells. In transgenic mice engineered to express the spliced isoform of XBP-1 through 
Eµ directed expression (an Eµ enhancer binds to specific proteins to increase their 
likelihood of transcription), multiple myeloma (MM) phenotypes were observed, 
including the premalignant precursor to MM; monoclonal gammopathy of 
undetermined significance (MGUS). The forced expression of spliced XBP-1 enhanced 
B-cell proliferative potential and activated known pathways of MM (Carrasco et al., 
2007). Interestingly, loss of function mutations in XBP-1 and IRE1α were discovered 
in multiple myeloma cell lines that showed resistance to proteasome inhibition 
(Leung-Hagesteijn et al., 2013). Proteasome inhibitors are used as a non-curative 
therapy for multiple myeloma which extends survival. The failure to cure MM with 
proteasome inhibitors was partially explained through the discovery of sub-
populations of pre-plasmablasts with XBP-1 loss of function that as a result are 
insensitive to proteasome inhibition. The cells with functioning XBP-1 show 
sensitivity to the protease inhibitors, which increase the already higher basal levels 
of ER stress in MM cells due to the inhibition of ERAD. However, in the 
subpopulations where XBP-1 has a loss of function mutation, the ER load is 
significantly less, due to a lower production of immunoglobulin (Ig) in these cells, and 
Ig synthesis plays the most prominent role in the ER of the plasma cells. This means 
that if less Ig is produced by these mutant plasma cells, they will not be sensitive to 
the increased ER stress induced by the proteasome inhibitors as they are avoiding 
the susceptibility to ER stress that arises from constant production of protein. The 
reason for a de-commitment to Ig production in XBP-1 knockdown is not clear, 
though this is the effect seen, and provides an explanation for the insensitivity to PIs. 
As previously discussed, the UPR has a large role in cell fate determination under 
stress conditions, and clearly, the active UPR in the hypoxic conditions of tumour cells 
plays an adaptive and pro-survival role in the disease. Pre-malignant cells harbouring 
mutations that inhibit the pro-apoptotic outcomes of the UPR may have selective 
advantages (Wang and Kaufman, 2014) due to irremediable UPR activation allowing 
constant survival of the tumour cells under stressed conditions. Because of the 
selective nature of UPR activation in the tumour cells and not in normal cells, 
targeting UPR activation in cancer could prove useful in selective cancer therapy (X. 
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Li et al., 2011). The key to potential UPR related therapy in cancer could lie in 
triggering the apoptotic pathways of the UPR over the adaptive pathways, 
stimulating cell death in the tumours. The issue with using this therapy is due to 
whether the selectiveness can be limited to solely cancer cells, and whether the 
desired apoptotic outcome for the cancer cells can be triggered with minimal 
downstream effects elsewhere. 
1.7.2 Ankylosing spondylitis 
Ankylosing spondylitis (AS) is a chronic inflammatory debilitating disease that affects 
the axial skeleton and often severely impacts the quality of life for sufferers. People 
with this disease have to cope with many related issues such as pain, functional 
disabilities and sleep problems (Sieper et al., 2002) amongst other socio-economic 
factors such as loss of income and additional disease related expenses (Sieper et al., 
2002). The prevalence of ankylosing spondylitis varies from region to region with a 
mean AS prevalence of 23.8 per 10,000 (0.238%) in Europe and 16.7 per 10,000 
(0.167%) in Asia (Dean et al., 2014). A main feature of the disease is enthesitis; an 
inflammation of the area where the tendons, ligaments, capsules and fascia 
incorporate into the bone (McGonagle, 2009) and along with other factors such as 
synovitis, subchondral marrow inflammation and osteitis this makes a painful disease 
that in severe cases can result in complete spinal fusion and rigidity. The role of MHC 
class I proteins in AS is subject to much research and scrutiny, as there is a clear link 
between the MHC class I gene HLA-B27*05 and the prevalence of AS. The normal 
function of MHC class I proteins is to present cytosolic non-self protein fragments to 
cytotoxic T cells, which elicits a rapid immune response, therefore bringing virally 
infected cells to the attention of the immune system (Hewitt, 2003). 
The pathophysiology of AS is still not fully understood, and there are multiple 
potential mechanisms that may cause the disease. There is certainly a strong genetic 
association with certain allotypes of the MHC class I allele HLA-B27 and AS. The MHC 
genes are encoded on chromosome 6 and the encoded proteins are present on all 
nucleated cell types (Shamji et al., 2008). The HLA loci are incredibly variable, and 
thus a different set of subtypes are expressed within each individual (Parham and 
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Ohta, 1996). Around 90% of ankylosing spondylitis sufferers are positive for HLA-B27; 
however, amongst HLA-B27 positive populations, only a small number of individuals 
(1.3% - 13.6%) suffer from AS (van der Linden et al., 1984),(Braun et al., 1998). The 
risk of developing AS amongst HLA-B27 positive individuals increases 16 fold with 
HLA-B27 positive relatives (van der Linden et al., 1984), and HLA-B27 positive 
individuals have a 20 fold higher risk of developing AS compared to negative 
individuals (van der Linden et al., 1984). The genetic link is clear, however there must 
be other contributing factors that work with HLA-B27 to cause progression of the 
disease as the prevalence statistics show that HLA-B27 does not directly cause the 
disease. A problem with the data from these two papers by Van der Linden et al. and 
Braun et al. respectively is that the sample sizes are small, and the variance in 
suggested percentage prevalence between the two papers reflects this. This paints a 
picture that AS is not present in all HLA-B27 positive individuals but there is an 
important link between the genotype and the disease that needs to be understood. 
Four main theories seek to explain the role of HLA-B27 in the pathogenesis of AS: 
arthritogenic peptide presentation, aberrant surface chains, protein misfolding and 
enhanced microbial survival (Shamji et al., 2008). Genetic information is important 
for understanding AS; for example, the change of the amino acid residue aspartate 
to histidine means that the allele from the AS associated HLA-B2705 changes to the 
HLA-B2709 allele which as a result loses the association with AS (Del Porto et al., 
1994). This observation is consistent with the arthritogenic peptide presentation 
theory, which suggests that the differences in peptide binding affinities between 
different allotypes of HLA-B27 can result in the presentation of unique self-peptides 
that exhibit molecular mimicry, resembling bacterial antigenic peptides. The mimicry 
of these peptides can lead to autoimmune cross reactivity due to the action of 
cytotoxic CD8+ T cells which causes tissue damage and inflammation (Shamji et al., 
2008). The aberrant surface chain theory suggests that the HLA-B27 protein has a 
tendency to form homodimers when the cell surface heavy chains lose β-
microglobulin, which occurs during endosomal recycling (Allen et al., 1999). These 
disulfide bridged homodimers elicit CD4+ T cell and NK cell autoreactivity which is 
destructive. The theory suggesting that the HLA-B27 phenotype enhances 
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intracellular microbial survival possibly has the weakest experimental support as 
there is a lot of conflicting evidence (Shamji et al., 2008). This theory proposes that 
ineffective peptide loading onto HLA-B27 can cause abnormal immune cell 
activation, which in turn allows bacteria and viruses to proliferate coupled with 
decreased clearance of antigenic peptides (Shamji et al., 2008). The final theory is 
that protein misfolding of HLA-B27 is a causative factor of ankylosing spondylitis. This 
theory suggests that the cellular ERAD response is exceeded, which results in 
commonly toxic misfolded aggregates forming inside and outside the cell. Chronic 
UPR activation here is a contributing factor towards AS, and there is evidence of 
increased UPR activation in transgenic rats expressing human HLA-B27 (Allen et al., 
1999). Prolonged UPR activation increases ERAD and pro-inflammatory NF-kB 
pathway activation (Shamji et al., 2008), and with the pro-survival arms of the UPR 
being favoured, the inflammation caused as a result is severe and chronic. 
Further effects of prolonged UPR stress on cells were explored in a paper by Lamech 
(Lamech and Haynes, 2015) which focuses on three stress response pathways in the 
cells; the heat shock protein response, the UPR and the mitochondrial UPR. This 
paper suggests there is a cytotoxic effect of continuous UPR stress. Multiple papers 
have also corroborated the link between misfolded HLA-B27 and UPR stress, 
including a 2007 study by Lemin et. al. (Lemin et al., 2007). This study demonstrated 
that the spliced form of XBP-1 is present in lymphocytes with over-expressed HLA-
B27. XBP-1 is important in regulating the most conserved branch of the UPR, the IRE1 
pathway (Lemin et al., 2007) which, as discussed, is key for cell fate determination. 
The data showed that XBP-1 was spliced in the HLA-B27+ cells suggesting that the 
unfolded protein response was active in these cells. Spliced XBP-1 is important for 
normal cytokine expression, and under ER stress it may be involved in synergistic 
induction (Colbert et al., 2014). In HLA-B27+ splenocytes from rats, there were higher 
levels of XBP-1 splicing than in the non-transgenic rats relatively speaking, albeit still 
with only a low absolute expression of spliced XBP-1 (Turner et al., 2007), further 
suggesting that a low level of UPR is active in HLA-B27+ cells. 
A paper by the Australo-Anglo-American Spondyloarthritis Consortium et al (TASC et 
al., 2011), demonstrated that other genes are also involved in AS, uncovered from 
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GWAS (genome-wide association studies). One such gene, ERAP1, acts as a molecular 
ruler of sorts, trimming polypeptide precursors down to size for presentation as 
antigenic peptides on MHC class I molecules (Chang et al., 2005). ERAP could play a 
role in disease, potentially through aberrant peptide trimming. A recent paper by 
Schittenhelm et al (Schittenhelm et al., 2015) revisited the arthritogenic peptide 
theory and suggested that conversely to previous beliefs, a potential mechanism is 
due to a quantitative change in the peptides, not a change in the type of peptides 
binding. A recent paper by Cortes et al (Cortes et al., 2015) shows that ERAP1 loss of 
function arising from Erap deficiency has a protective effect against ankylosing 
spondylitis, reducing the presentation of an HLA-B27 immunodominant epitope due 
to a loss of ERAP1 trimming function. Recently, through these multiple genome wide 
association studies, 26 risk loci have been identified outside the MHC class 1 (Cortes 
et al., 2015), and more risk alleles of HLA-B are being discovered including B*07:02, 
B*13:02, B*40:01, B*40:02, B*47:01, B*51:01 and B*57:01 (Cortes et al., 2015).  
In addition to the arthritogenic peptide theory, the aberrant surface chain hypothesis 
involves specific proteins for example, the role of the KIR3DL2 protein, shown to be 
expressed on the NK and CD4+ T cells in HLA-B27+ patients. This protein recognises 
HLA-B27 homodimers (Chan et al., 2005), and therefore is important to the aberrant 
surface chain hypothesis which suggests that HLA-B27 homodimers are recognised 
by the autoreactive CD4+ T cells and NK cells. The KIR3DL2 protein therefore is one 
such receptor responsible for recognising HLA-B27 and contributing to AS. While 
there has been a large amount of in depth research on AS and the pathogenesis of 
the disease, there is still much to be learnt.  
It is clear that in the pathogenesis of AS, many factors play a role and the importance 
of cytokines must not be underestimated, specifically relating to the misfolded HLA-
B27 theory. The ER resident chaperone BiP/GRP78 is often induced by the signalling 
pathways invoked by the UPR and this chaperone may promote cytokine production 
from macrophages which causes inflammation (Zambrano-Zaragoza et al., 2013). 
Interestingly BiP levels are 2 times higher in transgenic HLA-B27 rat splenocytes 
(Turner et al., 2007), demonstrating a link to the UPR and AS. Increased and 
prolonged interaction between BiP and HLA-B27 activates both the ERAD pathway 
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and the inflammatory NF-kB pathway (Shamji et al., 2008). The pro-inflammatory 
cytokines involved in AS include TNF-α, IL-1 and IL-6. TNF-α levels are significantly 
higher in patients with AS (Zambrano-Zaragoza et al., 2013) demonstrated in 143 AS 
Taiwanese patients (Shiau et al., 2007) and 97 Iranian (Nicknam et al., 2009). Various 
single nucleotide polymorphisms have been studied of the TNFA gene, which shows 
a relationship between certain polymorphisms and AS. Specifically, the TNF-α 
polymorphisms at amino acid positions 238 and 308 are significantly decreased in 
individuals with AS and overrepresented in AS patients as compared to controls 
(Nicknam et al., 2009). However, these polymorphisms do not seem to have a 
relation to specific HLA-B27 subtypes. The -238 and -308 polymorphisms have been 
associated with higher TNF-α levels. and some  TNF-α polymorphisms are protective 
in AS. TNF-α inhibition by etanercept shows an improvement of symptoms in patients 
with AS (Gorman et al., 2002). This was investigated using a double blind study with 
a placebo group in which 80% of the treated group showed an improvement in spinal 
stiffness, enthesitis and quality of life. These improvements were seen in both the 
treatment time (4 months) and in the longitudinal study (subsequent 6 months). The 
placebo group only showed a 30% improvement in these indicators (Gorman et al., 
2002). 
MIF (macrophage migration inhibitory factor) is also a key player in AS. It is believed 
that this cytokine has an important role in oxidative stress. Stosic-Grujicic et. al. 
suggested that MIF has an important role in the pathogenesis of autoimmune 
diseases by inducing the production of NO (nitric oxide) which is an oxidative stress 
mediator (Stosic-Grujicic et al., 2008). To see if MIF played a role in AS, the levels of 
MIF were measured in AS patients in a study by Kozaci et al (Kozaci et al., 2009). 
Though the sample size of this study was small, it was found that the MIF levels were 
raised in 25 AS patients compared to 18 controls (12.2 ± 7.7 and 7.5 ± 3.7 ng/ml, 
respectively, p = 0.01), and IL-10 levels were lower (210.9 ± 100.4 vs. 527 ± 191 pg/ml; 
p\0.001) (Kozaci et al., 2009). MIF levels also correlated with BASMI, an index 
reflecting spinal mobility and disease activity. The authors concluded that MIF could 
potentially amplify or enhance the existing inflammatory signals in AS rather than 
actually contributing to the pathogenesis of AS. 
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While the four theories explaining the role of HLA-B27 in AS (arthritogenic peptides, 
aberrant surface chains, microbial evasion, and MHC class I misfolding) all have 
credence individually, it is highly likely that there is a lot of interplay between the 
various proposed mechanisms of disease. The common factor between the theories 
is the role of HLA-B27 which is undoubtedly linked to AS.  The presence of HLA-B27 
alone is not enough to induce AS, and there are many factors that work alongside the 
MHC class I protein to contribute to the formation of AS. There is undoubtedly a link 
between UPR activation and AS, which shows that as well as the involvement with 
cancer with chronic UPR activation contributing to tumorigenesis, the UPR also plays 
a role in inflammatory diseases. It is clear that some of the key factors that contribute 
to AS include stress signalling pathways, such as that of XBP-1 which is spliced under 
ER stress conditions and affects cytokine production. Cytokines are important too in 
the pathogenesis of AS, as many pro-inflammatory cytokines are involved in 
enhancing the inflammation encountered in AS. The multiple aspects underlying the 
pathogenesis of AS demonstrate that one lone therapy may not be enough to 
eradicate the disease. Instead, a synergistic approach that combines different 
therapies to target different facets should be employed.  
1.8 Stress inducers 
The pharmacological stress inducers tunicamycin and DTT both cause ER stress in the 
cell, however their mechanisms of action are different. Tunicamycin is an ER stress 
inducer that inhibits the initial steps of glycoprotein biosynthesis. It does this by 
inhibiting UDP-N-acetylglucosamine-dolichol phosphate N-acetylglucosamine-1-
phosphate transferase (GPT) (Oslowski and Urano, 2011). The treatment of cells with 
tunicamycin results in a build-up of unfolded glycoproteins in the ER, which 
ultimately triggers ER stress. The primary effect of tunicamycin is to trigger the UPR, 
which closely mimics the in vivo activation of the UPR by unfolded proteins. DTT also 
induces the UPR. It is a strong reducing agent that reduces disulphide bonds and 
prevents disulphide bond formation, though this inhibition is not limited to just the 
ER, making it a non-specific stress inducer (Oslowski and Urano, 2011). Multiple 
studies have demonstrated the usefulness of these drugs in ER stress induction, with 
tunicamycin inducing a slower onset of stress over a period of roughly 5 hours 
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(Oslowski and Urano, 2011), and DTT eliciting a faster response (B. Li et al., 2011). A 
plethora of studies use tunicamycin as an experimental tool to induce stress, and it 
has proved very useful in mimicking the environment of misfolded proteins in the ER 
that is prevalent in many ER stress linked diseases. 
While tunicamycin is the main stress inducer used in the investigations in this thesis, 
it is important to note that there are other ER stress inducers. Thapsigargin, for 
example, is also commonly employed as a stress inducer (Iurlaro and Muñoz-Pinedo, 
2016; Sano and Reed, 2013; Zhang et al., 2014). Thapsigargin specifically inhibits the 
endoplasmic/sarcoplasmic reticulum Ca2+-ATPase, which results in a decrease of 
calcium inside the endoplasmic reticulum. This means that calcium dependent 
chaperones in the ER like calnexin lose their chaperone activity (Oslowski and Urano, 
2011), resulting in an increase of unfolded proteins and consequently ER stress. 
MG132 is another stress inducer, which specifically inhibits proteasome activity 
resulting in decreased ERAD, therefore indirectly causing a build-up of unfolded 
proteins in the ER. 
1.9 Genistein 
Genistein is an isoflavone found in soy based foods (Spagnuolo et al., 2015) and a 
tyrosine kinase inhibitor, currently employed as a drug for use in chemotherapy trials 
on animals and in vitro to target cancers. Tyrosine kinases transfer phosphate from 
ATP to protein substrates. When functioning normally, tyrosine kinases have a role 
in enhancing sensitivity to apoptosis and regulating cell growth by preventing 
uncontrollable proliferation (Paul and Mukhopadhyay, 2004). Tyrosine kinases also 
have an important role in cancer; for example, cancers often harbour mutations that 
cause constitutive activation of tyrosine kinases. The consequence of this is a 
constant activation of pathways that disrupts the normal regulation of cell growth 
and apoptosis, and will push the cells towards uncontrollable proliferation, resulting 
in the development of cancers. Genistein is of interest as an anticancer agent 
because it can inhibit protein tyrosine kinase (PTK) signalling to attenuate cancer 
development (BANERJEE et al., 2008). Tyrosine kinases are manifold, and another 
target of interest is the MAPK pathway, which is also involved in ER stress. MAPK 
31 
 
(ERK, JNK and p38) can induce NF-κB and drive cells toward survival under stress 
stimuli (Seger and Krebs, 1995). P38 MAPK is tyrosine phosphorylated by the MAP 
kinase kinases MKK3 and MKK6 (Zarubin and Han, 2005). Inhibition of these tyrosine 
kinases with genistein could result in an inhibition of the MAPK pathway, which may 
promote apoptosis due to inhibition of MAPK phosphorylation.  
The high pleiotropy of genistein means it can alter apoptosis, the cell cycle and 
angiogenesis via a synergistic effect on multiple biochemical pathways involved in 
the development on cancer (Spagnuolo et al., 2015). However, many of its 
downstream effects are not fully understood. Apoptosis induction by genistein was 
achieved by downregulating the anti-apoptotic B cell lymphoma 2 (BCl2) protein and 
upregulating the pro-apoptotic BAX in gastric cancer cells (Zhou et al., 2004). 
Epidemiological studies have demonstrated that the intake of isoflavines through a 
soy based diet appears to lower the incidence of breast cancer in Asian women in 
particular (Wu et al., 2008). The particular type of soy food consumed may change 
the relative risk, but when 15 epidemiological studies on soy consumption and 9 
studies on isoflavines were compiled, it was found that intake of soy based products 
also reduced prostate cancer in men, with a relative risk of 0.74 (95% CI: 0.63, 0.89; 
P = 0.01). The protective effect of isoflavines was more prominent in Asian men, with 
a relative risk of 0.52 (95% CI: 0.34, 0.81; P = 0.01) compared to  0.99 (95% CI: 0.85, 
1.16; P = 0.91) for Western populations (Yan and Spitznagel, 2009).  
Previous studies have found that genistein can inhibit the induction of GRP78/BiP 
during ER stress (Zhou and Lee, 1998a). This may be due to the importance of tyrosine 
kinase signalling in the pathways that lead to the production of chaperones such as 
GRP78. TFII-I is a multifunctional transcription factor that binds to the ER stress 
response element (ERSE) which is highly conserved across the promoters for ER stress 
related genes, under ER stress conditions (Hong et al., 2005a). The GRP promoters 
that promote transcription of essential chaperones, for example, contain multiple 
copies of the ERSE. The TFII-I protein exhibits enhanced binding to the ERSE of the 
GRP promoters under ER stress conditions. Specifically, a conserved GGC motif is 
required for optimal binding and this is located in a 9 bp CG rich region of the ERSE 
(Parker et al., 2001). The activity of TFII-I is mediated by phosphorylation, and TFII-I 
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is phosphorylated at specific serine and tyrosine sites. The tyrosine kinase 
phosphorylation of tyrosine residues Tyr248 and Tyr611 is dependent on the kinase c-
Src (Cheriyath et al., 2002). Genistein has been shown to inhibit GRP78 production 
(Zhou and Lee, 1998a), and the known inhibitory action of genistein on tyrosine 
kinases may explain GRP78 inhibition due to the importance of tyrosine kinase 
signalling in TFII-I signal transduction. Indeed, it has been shown that genistein 
inhibits tyrosine kinase phosphorylation of two specific tyrosine residues on TFII-I 
linked to ER stress; Tyr248 and Tyr249, and that genistein can act as a general inhibitor 
of ER stress induction (Hong et al., 2005a) due to its inhibition of thapsigargin and 
tunicamycin induced GRP78 expression. Another possible mechanism by which 
genistein inhibits GRP78 production is via interference with the key transcription 
factor CBF/NF-Y (Zhou and Lee, 1998a), which also regulates the ERSE, binding to the 
closest CCAAT site closest of the GRP78 promoter. The treatment of cells with 
genistein does not appear to disrupt GRP78 already produced, and therefore 
genistein is likely just to inhibit further production of the chaperone. Genistein-
mediated inhibition of GRP78 transcription works through the ERSE, and highlights 
one particular role of tyrosine kinase activity in ER stress. Figure 1.3 shows how 
tunicamycin induces stress in the cell, and the possible effect of genistein on the 
stressed cell.  
 
Figure 1.3: The action of tunicamycin and the possible consequence of genistein treatment 
on the stressed cell. 
Tunicamycin blocks N-linked glycosylation and therefore causes a build up of unfolded 
glycoproteins which leads to the sequestration of BiP, activating the three possible UPR 
pathways (IRE1α, PERK, and ATF6α). Genistein is known to inhibit the production of more 




Previous research in the laboratory has suggested that genistein can modulate ER 
stress (Lemin, 2007). In the fibrosarcoma HT1080 human cell line, insufficient 
tunicamycin induced ER stress could be overcome by genistein, allowing the 
reactivation of stress signalling pathways and resolution of the cellular stress. In 
contrast, the cervical cancer HeLa cell line exhibited a robust response to tunicamycin 
and there was less of an obvious effect of genistein. The different outcome of 
tunicamycin-induced stress responses in the two cell types could be in part explained 
by genetic differences in the cells. If irremediable stress can be resolved by the 
addition of genistein, then there are certainly therapeutic implications in addition to 
the already known effect of genistein on cancer. For example, in the chronic 
inflammatory disease AS, there is clear evidence of UPR activation, and while this is 
not the complete picture, genistein could prove to be useful as a therapeutic agent 
if used in conjunction with other drugs targeting other aspects of the disease.  
1.10 Hypotheses and aims 
Through these investigations, the aim is to investigate the differential cell specific 
responses between HeLa and HT1080 cells to tunicamycin induced ER stress, and 
whether genistein could modulate this to any extent. These differences will be 
measured through investigating changes in expression of ER stress related proteins 
through western blotting, and through changes in cellular phenotype and cell motility 
via the use of live cell imaging. 
It is hypothesised that there will be specific differences in how both cell lines respond 
to tunicamycin induced stress, with protein expression levels changing in different 
ways for each cell line, as well as possible variances in how cell motility is affected. It 
is hypothesised also that genistein will rescue the effect of tunicamycin induced cell 


























2.1 Cell Culture 
Three cell lines were used throughout this study: human neonatal dermal fibroblasts 
(HDFs) isolated from neonate foreskin, cervical cancer HeLa cells and fibrosarcoma 
HT1080 cells. The HT1080 and HDF cell lines were grown in Dulbeco’s Modified Eagle 
Medium (DMEM, GibCo, Thermofisher Scientific) and the HeLa cell line was grown in 
Minimum Essential Medium (MEM, GibCo, Thermofisher Scientific). Both types of 
medium were supplemented with 100 units ml-1 of penicilin, 100 µg ml-1 of 
streptomycin, 2 mM glutamax (all GibCo, Thermofisher Scientific), and 8% foetal 
bovine serum (Sigma). To keep the cells alive, they were passaged twice a week on 
Mondays and Fridays, providing that they had reached 90% confluence. Confluency 
was assessed by observing how many cells were adherent to the surface of the flasks. 
To passage the cells, they were first washed in phosphate buffered saline (PBS) 
(Sigma) twice before adding 0.05% trypsin (GibCo Thermofisher Scientific) to the 
surface of the culture flasks. The cells were left to trypsinise for 2 – 5 minutes (the 
sensitivity of the cells varied), and once the cells had detached from the surface of 
the flask (ascertained by light microscopy), they were re-suspended in fresh medium, 
warmed to 37oC. The medium containing the cells was added to fresh media in new 
flasks at the dilutions of 1:2 for HDFs, 1:10 for HeLa cells, and 1:10 for HT1080s. All 
cell lines were culture in T75 flasks (Techno plastic products). 
2.2 Chemical Treatment of Cell Lines 
Cells were subjected to chemical treatments to induce or modify an ER stress 
response. For western blotting experiments, the cells were treated using different 
drugs for different time frames and for the spinning disc experiemnts all treatments 
were for 6 hours. The treatments were either the addition of dithiothreitol (DTT) at 
5 mM or tunicamycin at 1 µg ml-1. These treatments were applied both on their own 
and also in conjunction with genistein at 140 µM. For serum starving experiments, 
serum free MEM and DMEM was applied to the cells in the place of serum containing 
media for the duration of the chemical treatments. After washing the cells twice in 
PBS, medium containing the chemicals was added to fresh medium in 6 cm plates for 
lysis or 35mm µ-Dishes (Ibidi) for the spinning disc experiments.   
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2.3 UV treatment of cell lines 
To induce UV related stress, both HeLa and HT1080 cells were exposed to UV-C, 40 
J/m2 UV over 5 seconds, using an 8 watt bulb.  
2.4 Cell lysis 
Two different lysis buffers were used to lyse the cells, MNT lysis buffer and RIPA lysis 
buffer. MNT buffer is a general lysis buffer for protein extraction, however RIPA 
buffer is versatile as it enables extraction of cytoplasmic, membrane and nuclear 
proteins; the latter of which MNT lysis buffer cannot retrieve. MNT lysis buffer was 
composed of 20 mM MES, 30 mM Tris-HCl, 100 mM NaCl, 1% (v/v) Triton x100; 
supplemented with 1 µg/ml of the protease inhibitors: cystatin, leupeptin, antipain 
and pepstatin A (Sigma Aldrich) and 20 mM NEM to inhibit disulphide bonds 
reforming. RIPA buffer was composed of 1% (v/v) Triton x100, 50 mM Tris-HCl pH 8, 
150 mM NaCl, 0.5 % Na-deoxycholate, 0.1% SDS, supplemented with 1 µg/ml of the 
protease inhibitors: cystatin, leupeptin, antipain and pepstatin A (Sigma Aldrich) and 
1% Phostop (Roche) which contains a cocktail of phosphatase inhibitors. Prior to lysis, 
the cells were washed twice with PBS before being placed on a tray of ice. To start 
with, two hundred µl of lysis buffer was applied and the cells in the dishes scraped to 
encourage lysis. The sample lysates were then centrifuged for 10 minutes at 4 oC and 
16,100 g to separate the nuclear pellet from the rest of the lysate. The supernatant 
was then be removed and flash frozen to be used later on for SDS-PAGE and Western 
Blotting.  
2.5 BCA Assay 
The BCA assay (Thermofisher Scientific) was used to quantify protein concentration 
in cell lysates. A colour change from green to purple is seen in the assay, which works 
through the highly selective sensitive colorimetric capability of the cuprous cation 
(Cu+1). This uses the bicinchoninic acid (BCA) contained in the working reagent, in 
combination with the biuret reaction; the reduction of Cu+2 to Cu+1 by protein when 
in an alkaline medium. The colour change to purple is seen because two BCA 
molecules are chelated with a cuprous ion. This colour change shows a linear 
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relationship with protein concentration and was therefore a suitable method to use 
(“Pierce BCA Protein Assay Kit - Thermo Fisher Scientific,”).  
For a typical protein determination assay, nine BSA protein standards of increasing 
concentrations (0, 25, 125, 250, 500, 750, 1000, 1500, 2000 µg/ml of BSA) were 
prepared. The working reagent consists of working reagent A and B and these were 
mixed using 50 parts of reagent A and 1 part of reagent B (50:1). The standards were 
made with different dilutions of the same lysis buffer that was used to lyse the cells, 
along with a 2 mg ml-1 albumin standard. Once made, 50µl of the standards and 
samples were placed into appropriately labelled Eppendorf tubes along with 1 ml of 
the mixed working reagent. These were then incubated for 30 minutes at 37oC and 
afterwards removed and cooled to room temperature. Once cooled, a 
spectrophotometer set to the BCA setting (562 nm) was used to measure the 
absorbance, starting by blanking the machine to the standard I (which contains no 
protein) and reading the rest of the standards first before measuring the samples. 
Then using graphical software, a standard curve was plotted and the protein 
concentration of the samples was measured.   
2.6 Sample preparation 
To prepare the samples for gel electrophoresis, frozen lysates were thawed slowly 
on ice to reduce protein degradation, and fresh lysates on ice were used straight 
away. For each lysate, the protein concentration was used to calculate the volume of 
lysate needed in each sample to achieve a uniform final protein concentration. This 
was calculated for every sample using the standard curves obtained from the BCA 
assays. Gel electrophoresis samples were then prepared using 2× Laemmli sample 
buffer (4% (w/v) SDS, 20% glycerol, 120 mM Tris-Cl, 0.02% (w/v) bromophenol blue 
(BioRad)) and 50 mM DTT (to reduce disulphide bonds) and the lysate plus lysis buffer 
if required to equalise protein concentrations.  Samples were boiled for 5 minutes at 
95oC in a heating block, then centrifuged for 5 minutes at 16,100 g. The samples were 




To analyse proteins by Western blotting or Coomassie staining, the proteins in the 
samples were separated out by SDS-PAGE, which allows separation of the proteins 
according to size. This is achieved by running a voltage through a gel, causing 
negatively charged proteins to migrate away from the negative electrode (cathode) 
and towards the positive electrode (anode). The proteins are separated out by size 
due to smaller proteins being able to migrate more easily though the pores in the gel. 
The proteins become negatively charged through the addition of sodium dodecyl 
sulphate (SDS) into the gel mixture, which disrupts covalent bonds in the proteins 
and denatures them. 
A Hoefer mighty small dual gel caster was set up with glass and ceramic plates to cast 
10% SDS-PAGE gels. Table 1 shows the quantities of each chemical needed for 10% 
resolving gels, with a quantity enough to cast 2 gels. 
Table 2.1: Volumes of solutions used to cast 10% SDS-PAGE gels.  
 10% resolving gel stacking gel 
H2O 4.8 ml 2.2 ml 
40 % Acrylamide 2.5 ml 0.4 ml 
1.5 M Tris (pH 8.8) 2.5 ml 0.4 ml 
10% SDS 0.1 ml 0.03 ml 
10% APS 0.1 ml 0.023 ml 
TEMED 0.004 ml 0.002 ml 
 
Once set, the gels were taken out of the casting kit and moved to the electrophoresis 
apparatus (Hoefer mighty small basic unit 8 × 7 cm). Pre-chilled running buffer (25 
mM Tris, 192 mM Glycine, 0.1 % (w/v) SDS; BioRad) was then poured into the central 
chamber of the apparatus and into the bottom reservoir, ensuring that there was 
buffer in the wells of the gel. After taking the comb out, 6 µl of molecular weight 
marker (Precision Plus Protein™ Dual Color Standards, BioRad) containing a mixture 
of 10 recombinant proteins (10 – 250 kDa)) was loaded alongside the samples. For 
the 10-well comb gels, 20µl of sample was loaded and for the 15-well comb gels, 10µl 
of sample was used. 
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Once loaded, the gel was run at 40 mA for ~1 hour, until the dye front reached the 
bottom of the gel. The gels were then removed from the plates for use in either 
Western Blotting or Coomassie staining.  
2.8 Coomassie Staining. 
Coomassie brilliant blue staining was used to visualise the proteins after SDS-PAGE. 
The coomassie dye binds to the proteins, which stabilises the anionic (negatively 
charged) form of the dye which results in the production of a  blue colour (Chial et 
al., 1993). For the coomassie staining process, the gels were placed in a tray 
containing fixating solution (7% acetic acid and 40% methanol, made to 50 ml with 
dH20) and rocked for 10 minutes in a fume hood. After this, the gels were transferred 
to a tray containing the coomassie stain (80% brilliant blue G colloidal (Sigma) made 
to 50 ml with dH2O) and left on a rocker to stain overnight. Because the coomassie 
stains the polyacrylamide gel as well as the proteins, destaining was required. This 
was done by leaving the stained gels in destain solution (10% acetic acid, 25% 
methanol, made to 50ml with dH2O) for 10 minutes and then leaving the gel 
overnight in a secondary destain (25% methanol made to 50ml with dH2O). Once 
destained, the gel could be removed and scanned onto a computer using a CANON 
LiDE 120 scanner.  
2.9 Western Blotting 
Western blotting was used to transfer the proteins from an SDS-PAGE gel to a PVDF 
(polyvinylidine difluoride) membrane, which was then probed for the expression of 
proteins of interest. The transfer step of the western blotting works through 
electroblotting, which uses an electrical current to pull the proteins in the gel onto 
the PVDF membrane. After transfer, non-specific membrane binding was blocked by 
incubating the membranes in a 5% milk solution. Then the proteins on the membrane 
were probed with a primary antibody, specific for a target protein or group of 
proteins. To visualise the protein expression, a secondary antibody conjugated to 
horseradish peroxidase (HRP) was applied to the membrane, and this binds to a 
species-specific region on the primary antibodies attached to the protein of interest. 
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The horseradish peroxidase catalyses a chemiluminescent ECL reaction, which 
luminesces in proportion to the antigenic protein concentration. A strip of 
photographic film was laid over the membranes once they had been incubated with 
the ECL solution and the exposure was made for different times according to protein 
expression levels. Figure 1 highlights the key features and principals behind SDS-
PAGE and western blotting. 
For every gel, 4 pieces of filter paper and 1 piece of PVDF membrane (pore size 0.45 
µm (Millipore)) were cut to the same size as the gel. Ten minutes before transfer, the 
PVDF membrane was primed in methanol for 30 seconds, and then placed in a tray 
containing pre-chilled transfer buffer (25 mM Tris-base, 190mM glycine, 20% 
methanol, made to 1 litre with dH2O), where it was soaked for 10 minutes. When 
ready for transfer, a transfer cassette was prepared with two sponges (one on each 
side), four pieces of filter paper (two on each side) and the PVDF membrane (towards 
the anode). The membranes were soaked in transfer buffer before placing the 
washed gel on top of the PVDF membrane. The cassette was closed and loaded into 
the transfer kit (Mini Trans-Blot®; BioRad) which was filled with transfer buffer and 
kept cold with an ice pack. The transfer was carried out for 2 hours at 150 mA or 
overnight at 30 V and 4o C.  
After transfer, the PVDF membrane was removed from the transfer apparatus and 
blocked by incubating it in 5% dry, nonfat milk in 1×TBS-T (0.1% v/v) Tween, 150 mM 
NaCl, 2.68 mM KCl, 10 mM Tris base) for one hour. Depending on the antibody, the 
membrane was washed in TBS-T three times before incubating in the primary 
antibody.  The primary antibody was diluted to the required amount (see Table 2.2) 
in either 1 ml of 5% milk and 2 ml of TBS-T, or 5% BSA in 1× TBS with 0.1% Tween. 
After the first incubation, the primary antibody mix was removed and the 
membranes washed 5 times in TBS-T, allowing 5 minutes on a roller for each wash. 
The secondary antibody dilution was then prepared, using GAMPO (goat anti-mouse 
peroxidase; DAKO) if a murine monoclonal primary antibody was used, or SARPO 
(swine anti-rabbit peroxidase; DAKO) if a polyclonal rabbit primary was used. The 
secondary antibodies were both diluted to 1:3000 in 1 ml of 5% milk and 2 ml of TBS-
T, and the membranes incubated for another hour. Once this incubation step was 
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complete, the membranes were washed 5 times in 5 ml of TBS-T for 5 minutes each, 
then they were removed from the tubes and placed in a tray of TBS for 10 seconds 
before being dabbed on tissue paper and placed onto saran wrap. An ECL solution 
was made by mixing 250 µl of detection reagent 1 and 250 µl of detection reagent 2 
(Amersham ECL Prime Western Blotting Detection Agent) to make 500 µl of ECL per 
membrane, which was spread over the membrane by folding over the saran wrap 
and smoothing the mix out over the membrane. The membranes were then 
removed, the excess ECL dabbed off and the membranes placed on fresh saran wrap. 
A phosphorescent sticker was attached to the corner to allow alignment of the blot 
after development. The wrap was then cut to the size of the membrane, placed in a 
cassette and exposed to photographic film (Kodak) in a darkroom. Common exposure 
times were 30 seconds, 2 minutes and 5 minutes, though this varied according to the 
antibody and experiment. The photographic film was then processed using an X-










Figure 2.1: Simplified diagram showing the process of SDS-PAGE (left) and Western 
blotting (right). The samples are run through a gel alongside a molecular weight marker, 
and they migrate towards the positive anode. Once the proteins are separated they are 
transferred to a PVDF membrane (step not shown), which is probed for a target protein 
using primary and secondary antibodies. 
2.10 Antibodies 
Multiple primary antibodies were used for protein detection in the western blots. 
Table 2.2 shows detailed information about the antibodies used. 
2.11 Live Cell Imaging Microscopy 
To study cell morphology and the response to ER stress, cellular behaviour was 
monitored using live cell imaging. Time lapse movies of HT1080 or HeLa cells were 
taken over an extended period of time to investigate cellular behaviour e.g. motility 
and ER morphology. Cells were grown on 35 mm µ-dishes with glass bottoms (Ibidi) 
and were washed twice with PBS, before applying the lipid staining ER-Tracker Blue-
White DPX (Thermofisher) dye at a 1:800 dilution in fresh DMEM or MEM medium. 
The cells were incubated with the dye for 1 hour. The dye is specific for the 




Table 2.2: Table showing all the antibodies used in this thesis.  
The manufacter, the dilution of primary and secondary antibody, used, the incubation time, 
and the medium required for incubation are also shown. 








1:2000 GAMPO Overnight 5% BSA in 






1:2000 SARPO Overnight 5% BSA in 






1:1000 SARPO Overnight 5% BSA in 
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1:1000 SARPO Overnight 5% BSA in 






1:2000 GAMPO Overnight 5% BSA in 







1:2000 SARPO Overnight 5% BSA in 
1× TBS with 
0.1% Tween 
PYCOX Abcam 1:10000 SARPO Overnight 5% BSA in 
1× TBS with 
0.1% Tween 
HC10 (Stam et al., 
1986)* 
1:200 GAMPO 1 Hour 5% milk in 
1× TBS with 
0.1% Tween 
W632 (Barnstable et 
al., 1978)* 
1:200 GAMPO 1 Hour 5% milk in 
1× TBS with 
0.1% Tween 
1B5 * 1:1000 GAMPO 1 Hour 5% milk in 
1× TBS with 
0.1% Tween 
BiP Santa Cruz 
Biotechnology 
1:500 GAMPO 1 Hour 5% milk in 
1× TBS with 
0.1% Tween 
GRP94 Cell Signalling 
Technology 
1:1000 SARPO Overnight 5% milk in 
1× TBS with 
0.1% Tween 
Β-Actin Abcam 1:10000 GAMPO 1 Hour 5% milk in 
1× TBS with 
0.1% Tween 
PDI (Benham et al., 
2000) 
1:1000 SARPO 1 Hour 5% milk in 




* A gift from Prof. J. Neefjes, Netherlands Cancer Institute, The Netherlands 
After a 1 hr incubation, the cells were again washed twice with PBS before treating 
them with ER stressors as described in section 2.2. The CO2 levels of the incubation 
chamber were set to 5% at 3 litres per hour and the temperature was set at 37.4oC.  
An Andor Revolution XD spinning disc confocal microscope was used to image the 
cells. The microscope was set to an exposure of 60 ms, a laser exposure intensity of 
25, and an EM gain of 300.  
The absorbance and emission spectra of ER-Tracker Blue-White DPX can be seen in 
Figure 2 and the 405 nm laser was selected to visualise the dye with the microscope. 
The imaging was carried out for 6 hours, with a photograph of the cells being taken 
every minute, resulting in a time-lapse movie composed of 360 frames. 
2.12 Data Analysis 
To track the movement of the cells, the ImageJ plugin MTrack2 was used which 
allowed tracking of individual cells by moving through each frame of the time-lapse 
movie and creating a path for each cell by clicking on its location for each frame. 
Every visible cell was tracked, and once the scale had been set, it was possible to view 
the Len values (length in µm) for each cell’s pathway. 
These values were then inputted into Graphpad’s Prism software, where the 1-way 
ANOVA T-test was used to determine if there were any significant differences 
between the conditions, and Tukey’s test was used to individually compare each 
condition to all other conditions and determine which treatments had significant 
differences with others.  
The parametric one-way ANOVA T-test was used due to its ability to compare 
significance between multiple groups at once. The one-way ANOVA T-test assumes 
that the data is normally distributed, and to test for this, the D’Agostino and Pearson 
normality test was used on the data. This test demonstrated that the data was 






















3.1 Investigation into the change of downstream protein expression 
between HeLa and HT1080 cells after induced ER stress. 
3.1.1 Initial investigation into the action of tunicamycin and DTT on the expression 
of UPR associated chaperones and MHC class I glycosylation. 
The preliminary experiments were designed to investigate the effect of DTT and 
tunicamycin on the stress response of HT1080 and HeLa cells (Figure 3.1.1). The cells 
were treated with medium supplemented with either DTT for 30 minutes or 
tunicamycin for 6 hours, based on previous research in the laboratory. It has been 
shown that induction of XBP1 processing by DTT was effective in both cell lines after 
30 minutes of 5 mM DTT treatment; however, the induction of XBP1 processing by 1 
µg/ml tunicamycin was efficient in HeLa cells but not HT1080 cells, indicating that 
the two cell types differ in their response to dysregulation of N-linked glycosylation 
(Lemin et al FEBS Lett and unpublished). Cell lysates were analysed by SDS-PAGE 
followed by immunoblotting to ascertain the expression of MHC class I molecules, 
and two heat shock proteins, GRP78/BiP and GRP94 (Hsp90). β-actin expression was 
used as a control to demonstrate the equal loading of protein across the samples. 
Antibodies raised against GRP94 and BiP/GRP78 were used to investigate chaperone 
expression in the cells. BiP and GRP94 are ER resident chaperones, and both are 
heavily linked to ER stress, with roles in assisting ERAD and interacting with ER folding 
proteins (Eletto et al., 2010).  
GRP94 could be detected in both cell lines, whereas the detection of BiP was variable, 
and reproducible results with the santa-cruz anti-BiP antibody (catalogue number sc-
13539) could not be achieved. The GRP94 expression was slightly raised in DTT and 
Tun treated HT1080 cells, but this was not significant when compared to the actin 
control (Figure 3.1.1, compare lanes 1 and 3). It is also possible that the expression 
of GRP94 even went down slightly in the HeLa cells with the DTT and tunicamycin 
treatments, however the small fluctuations were not reproducible in subsequent 
experiments. MHC class I expression was detected with the HC10 antibody, raised 




Figure 3.1.1: The effect of Tunicamycin and DTT on GRP94, BiP and MHC class I 
glycosylation. 
Western blot of HT1080 and HeLa cell lysates from cells treated with either DTT (lanes 2 and 
5) or tunicamycin (lanes 3 and 6) or untreated (lanes 1 and 4) to detect B-Actin (first panels), 
GRP94 (second panels), BiP (third panels) and MHC class I heavy chains (fourth panels). UT = 
Untreated, Tun = 6 hours 1 µg/ml tunicamycin, DTT = 30 minutes 5 mM DTT. GRP94 is 







































































































































lines as expected. It was hypothesised that the addition of tunicamycin might 
decrease the molecular weight of a subset of immature heavy chains, since 
tunicamycin inhibits the early stages of N-linked glycosylation. No decrease in 
molecular weight could be visualised, probably because of the heterogenous nature 
of the total MHC heavy chain pool. However, there was a small and reproducible 
decrease in the total class I pool from tunicamycin treated cells when compared with 
DTT treated cells (see also Figure 3.1.3). The samples shown in Figure 1 were also 
analysed by Coomassie staining (Figure 3.1.2). This acted as an extra control to 
demonstrate consistent loading. While faint, the Coomassie confirmed that the 
samples had been loaded equally, and that the BCA assay used to equalise protein 
concentration was accurate.          
3.1.2 Investigation into the effect of ER stress on downstream tyrosine 
phosphorylation and Stat3 expression.                  
Previous research in the laboratory suggested that DTT and tunicamycin induce 
different downstream stress responses in HT1080 and HeLa cell lines. Preliminary 
evidence suggested that changes in tyrosine phosphorylation could be involved 
(Masose and Benham, unpublished results). To investigate this further, HT1080 and 
HeLa cells were Mock treated, treated for 30 minutes with DTT, treated for 30 
minutes with tunicamycin and treated for 6 hours with tunicamycin (Figure 3.1.3). In 
addition to these treatments, both the HT1080 and HeLa cells were UV treated (UV-
C, 60 J/m2) to induce a stress response as a positive control (Tournier et al., 2000). β-
Actin was used as a loading control (Figure 3.1.3, first panel) and demonstrates equal 
loading of the samples. The expression of MHC class I heavy chains diminished 
somewhat after 6 hours of tunicamycin treatment, most noticeably for the HT1080 
cells (consistent with Figure 3.1.1). The status of Stat3 was assessed, because Stat3 
is a cell cycle regulator that controls autophagic responses in stressed cells, and 
induces pro-inflammatory cytokines (Meares et al., 2014). Blotting with an antibody 
raised against Stat3 revealed two bands in both HT1080 and HeLa cells: a strong band 
at around 86 kDa and a weaker shadow band at around 79 kDa (Figure 3.1.3, lanes 3 
and 7). These are likely to be two isoforms of Stat3; the upper - Stat3α (86kDa) and 
the lower - Stat3β (79kDa).  
50 
 
Figure 3.1.3: Stat3 expression dips in the 6 hour tunicamycin treatment for both cell lines. 
Western blot of HT1080 and HeLa cell lysates from cells treated with either UV light (lanes 1 
and 2), DTT (lanes 4 and 8) or tunicamycin (lanes 5,6 and 9.10) to detect B-Actin (first panel), 
MHC class I heavy chains (second panel), Stat3 (third panel) and P-Tyrosine (fourth panel). 
UT = Untreated, UV = UV-C, 60 J/m2, T30 = 30 minutes 1µg/ml tunicamycin, T6 = 6 hours 1  
µg/ml tunicamycin, DTT = 5 mM DTT. HC10 is observed at a molecular weight of around 48 











The difference in function between these isoforms is unknown. Both are produced 
from the same gene product via alternate splicing. However Stat3β has prolonged 
nuclear retention compared to Stat3α (Huang et al., 2007). Figure 3 suggests that the 
Stat3β isoform decreased after 6 hour tunicamycin treatment in the HT1080 cells and 
decreased after 30 minutes and 6 hours of tunicamycin treatment in the HeLa cells. 
In the HT1080 cells, the Stat3α isoform expression seemed to decrease after 6 hours 
of tunicamycin treatment. The levels of Stat3α were elevated in the UV controls 
indicating a differential stress response to tunicamycin compared to UV stress. It 
would appear that the Stat3β isoform is more susceptible to stress related 
suppression of expression, and this seems to be specific to tunicamycin due to the 
absence of any effect with DTT. Further experiments will be required to determine 
the functional significance of this change in expression. 
 Next, tyrosine phosphorylation was investigated using a pan phospho-tyrosine 
antibody that detects all phosphorylated tyrosine kinases. This was performed to 
examine if there were any changes in the level of tyrosine phosphorylated proteins 
between stress treatments and cell lines. The pan-Tyr100 antibody gave variable 
results, though when comparing the untreated HT1080 cells with the UV control, 
there seemed to be induction of a protein at around 200 kDa (Figure 3.1.3 white 
arrow) after UV induced stress. In the HeLa cells, there was already a higher level of 
expression of this protein. Due to inefficient transfer at the top right hand corner of 
this blot, it was not possible to conclude whether this protein was expressed after 
the 6 hour tunicamycin treatment in the HeLa cells. Figure 3.1.4 shows a Coomassie 
gel of the lysates analysed in Figure 3.1.3 as an additional loading control. The band 
that seems to increase in prominence may be due to residual BSA in the media.  
3.1.3 Genistein  
Previous experiments in the laboratory have suggested that the isoflavone genistein 
can potentiate the effect of tunicamycin-induced ER stress in HT1080 cells (Lemin, 
Masose, Benham, unpublished observations). To assess whether the changes in Stat3 
and GRP94 expression could also be modulated by genistein, HeLa and HT1080 cells 
were subjected to 30 minutes mock treatment, 30 minutes 5 mM DTT, 10 minutes 1 
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µg/ml tunicamycin, 30 minutes 1 µg/ml tunicamycin, and 6 hours 1 µg/ml 
tunicamycin, all with or without 140 µM genistein (+/-). The cells were lysed after 
treatment and the lysates subjected to western blotting (Figure 3.1.5). The β-actin 
control shows that protein recovery and loading was equal in all lanes for these 
samples (3.1.5, first panel). The chaperone GRP94 was examined and the blot 
suggests that genistein may reduce the expression of this chaperone to some extent 
(lanes 2,8,10,14,18 and 20). In the HT1080 cells, the genistein treatment on its own 
(UT+) seemed to result in less GRP94 expression than the mock without genistein, 
and though this could be an air bubble (lane 2), that pattern is reflected in the 30 
minute (lane 8: T30+) and 6 hour tunicamycin (lane 10: T6+) with genistein when 
compared to those treatments without genistein, albeit to a lesser extent. The HeLa 
cells treated for 30 minutes and 6 hours with tunicamycin also show the same pattern 
as the HT1080 cells, with the addition of genistein seemingly decreasing the amount 
of GRP94 present. This corroborates with the fact that genistein regulates the DNA 
binding affinity of CBF/NF-Y; a transcription factor that binds to the promoter of 
GRP78 as well as GRP94 (Zhou and Lee, 1998b). GRP94 production has also been 
shown to be dependent on the presence of the transcription factor TFII-I, which is 
also a possible target for the inhibitive effects of tunicamycin (Hong et al., 2005b). 
The inverse of this pattern seems to be the case however in the other HeLa conditions 
with genistein increasing GRP94 expression in the untreated (lane 12: UN+) and 10 

















































































































































In the Stat3 blot, the two isoforms of Stat3 were present, and in the HeLa cells, the 
shadow band – Stat3β again decreased slightly in the 6 hour tunicamycin treatment 
(lanes 19, 20: T6+/-), however there was not an observable decrease in the 30 minute 
tunicamycin which contrasts with the decrease seen in the first Stat3 blot. The 
HT1080 cells did not seem to show any noticeable decrease; however, due to the 
high intensity of the bands, it is difficult to make this a certain conclusion.  
Interestingly, there was an additional band seen in the HeLa cells that was not seen 
in the first Stat3 blot. This band appears just below 150 kDa (labelled with the white 
arrow) and acted as a useful control in subsequent experiments, however there was 
not enough time to fully explore the identity of this band. 
 Given that tunicamycin-induced changes in glycosylation were difficult to 
visualise with the MHC class I antibody HC10, PCYOX was investigated as a putative 
indicator of immature N-linked glycosylation status, as PCYOX is lysosomal 
oxidoreductase with 3 N linked glycans.  The PCYOX antibody (Figure 3.1.5, fourth 
panel) did not detect a major difference in the molecular weight of PCYOX when 
comparing untreated cell lysates with tunicamycin treated cell lysates (compare 
lanes 1 and 2 with 5-10 and 11 and 12 with 15-20). There may have been a small 
decrease in the migration of the protein upon treatment with DTT (due to reduction; 
compare lanes 11 and 12 with lanes 13 and 14). Pulse-chase experiments and 
experiments using lower percentage polyacrylamide gels would be required to 
explore this further. With the HeLa cells, there does seem to be an increase in 
migration after 6 hours of tunicamycin treatment (lanes 19,20: T6+/-). This could 
indicate a lower molecular weight which is possibly due to inhibition of glycosylation.  
A coomassie stained gel of the lysates shown in Figure 3.1.6 showed equal protein 


























































































































































































































































































Having observed some changes in the appearance of STAT3 isoforms after stress 
treatments, the phosphorylation status of STAT 3 was examined in HT1080 and HeLa 
cells that had been treated with tunicamycin (Figure 3.1.7). Firstly, the Stat3α 
isoform (86 kDa) followed a similar pattern to the first Stat3 blot, with the HT1080 
cells particularly showing a decrease in Stat3α expression after the 6 hour 
tunicamycin time point (lane 8: T6). The HeLa cells also showed a decrease in Stat3 
expression after 6 hours of tunicamycin treatment (lane 7: T6) but possibly to a lesser 
extent. This result shows that the decrease in the expression of the Stat3α isoform in 
the HT1080 cells particularly, is reproducible. The Stat3β isoform also showed a 
reproducible decrease in expression in both cell lines after the 6 hour tunicamycin 
treatment (lanes 7,8: T6) but the HeLa cells did not show a noticeable decreased 
expression of the Stat3β isoform after the 30 minute tunicamycin timepoint (lane 5: 
T30) which was seen in the first Stat3 blot. The unidentified ~150 kDa band appeared 
in all the HeLa lysates, but not the HT1080 lysates (Figure 3.1.7, second panel, 
compare lanes 1, 3 , 5 and 7 with lanes 2, 4, 6 and 8). This result acted as a control to 
demonstrate correct loading. The Stat3 result again showed a decreased expression 




























Figure 3.1.6: Coomassie gels loaded with lysates created from Genistein, DTT and Tunicamycin 
treated Hela and HT1080 cells. 
Coomassie Brilliant Blue stain of gels loaded with HeLa (first panel) and HT1080 (second panel) cell 
lysates from cells treated with DTT (lanes 3,4) and tunicamycin (lanes 5-10). UT = Untreated, T10 = 
10 minutes T1 µg/ml tunicamycin, 30 = 30 minutes 1 µg/ml tunicamycin, T6 = 6 hours 1 µg/ml 













































































































































































































The P-Stat3 blot did not seem to reflect the Stat3 pattern, with an unexpected 
appearance of P-Stat3 expression in the HT1080 cells, showing induction of P-Stat3 
in the HT1080 untreated sample and then a dip in expression in the 10 minute 
tunicamycin sample. Another rise of expression was seen in the 30 minute and 6 hour 
tunicamycin samples. This seemed to indicate that there was a baseline expression 
of P-Stat3 in the mock HT1080 cells that then undergoes an immediate dip and 
subsequent rise over time. In contrast, the HeLa cells showed a delayed induction of 
P-Stat3 in the 6 hour tunicamycin sample. It is possible that HT1080 cells have an 
elevated baseline expression of P-Stat3 and Stat3 in general compared to HeLa cells, 
and that tunicamycin has the immediate effect of reducing these expression levels, 
with a resurgence of P-Stat3 occurring later on. This indicates a potential build-up of 
irremediable stress after an initial UPR adaption of the cell. It appears that the UPR 
is already active to an extent in the HT1080 cells but it may be the case that it is in a 
chronic state of UPR activation, as seen by the high baseline level of P-Stat3. A 
previous study on the induction of P-Stat3 in astrocytes using the pharmacological 
stress inducer thapsigargin seemed to indicate a peak of P-Stat3 expression at around 
2 hours (Meares et al., 2014).  It is possible that these results reflect both acute and 
chronic effects of P-Stat3 induction, particularly in the HT1080 cells. The HT1080 cells 
contain an endogenous N-Ras mutation that may be causing constitutive P-Stat3 
activation, which could account for the signal seen in the untreated HT1080 cell 
lysates (Gupta et al., 2000). This will be discussed further in the discussion.  
3.1.4 Phosphorylated MAPK p44/42 expression is transiently increased after 
tunicamycin induced stress.  
The same lysates were analysed by western blot using the PathScan® PDGFR activity 
assay (Figure 3.1.8). This cocktail of antibodies detects the activation of multiple 
pathways including phospho-p44/42 MAPK, phospho-SHP2 and phospho-Akt. These 
cells were not stimulated with the addition of PDGF and therefore phosphorylation 
of PDGFR was not detected. The results suggest that DTT and tunicamycin treatment 
do not result in the non-specific induction of the PDGFR receptor. Interestingly, 




















































































































































































































































































very clear peak of phosphorylated p44/42 MAPK expression in both cell lines after 10 
minutes of tunicamycin treatment (Figure 3.1.8, lanes 5,6 and 15,16: T10+/-). The 10 
minute tunicamycin treatment was included because through other work in this 
laboratory, it was found that tunicamycin induced a peak of phosphorylated 
MAPK/p44/42 expression at 10 minutes, and therefore this time point was included 
to see if a short-term ER stress response was occurring. This blot indicated that there 
was a baseline activation of P44/P42 MAPK in the untreated samples in both cell 
types. Even with this baseline MAPK phosphorylation, the peak signal in the 10 
minute tunicamycin treatment was very clear in both cell types. Both cell lines 
seemed to exhibit a dip in MAPK phosphorylation after the 10-minute peak, with the 
30 minute tunicamycin treated HT1080 cell signal (lanes 17,18: T30+/-) falling to a 
similar level of phosphoprotein expression as the untreated cells (lanes 11,12: UT+/-
). Another smaller rise in MAPK and P44/P42 activation was observed in the 6 hour 
tunicamycin treated HT1080 cells. The Hela cells, on the other hand, had a smaller 
reduction in phosphorylated p44/42 expression in the 30 minute tunicamycin lysates 
(lanes 17,18: T30+/-), with the expression at 6 hours of tunicamycin treatment (lanes 
19,20: T6+/-) less than the level of expression observed in the untreated lanes (lanes 
11,12: UT+/-).  
The HT1080 and HeLa cells exhibited slightly different patterns in phosphorylated 
p44/42 expression within the tunicamycin treatments (Figure 3.1.8), and with the 30 
minute DTT treated samples there seemed to be a difference too, with the HT1080 
cells dropping in phospho-p44/42 expression but the HeLa cell signal rising slightly. 
When comparing the effect of the addition of genistein to the cells, it had little effect 
on phosphorylated p44/42. The only exception to this would appear to be after 6 
hours of tunicamycin treatment, where the addition of genistein to HeLa cells 
induced an increase in phospho-p44/42 expression compared to the 6 hour 
tunicamycin sample without genistein. The internal eIF4E loading control was 
detected in all the samples, with the only potential difference being in the samples 
in lanes 10, 11 and 20, which could be due to uneven protein transfer to the 
membrane. If the loading was normalised, it would appear that the HT1080 6 hour 
tunicamycin sample with genistein showed an increased expression of MAPK. 
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A component of the pro-survival pathway, PI3K/AKT (Dai et al., 2010) was visible in 
this blot due to the probe for the phosphorylated AKT protein. Observation of the 
phosphorylation pattern of this protein could suggest whether genistein potentiates 
the ER stress response and pushes the cells towards a particular fate (e.g. apoptotis).  
The phospho-AKT protein can be seen in this blot, however it is fainter than MAPK, 
and the phospho-P44/P42 bands are thus harder to interpret. As seen from the 
phospho-P44/P42 bands, the 10 minute tunicamycin treatment seemed to induce a 
similar peak of expression in the phospho-AKT in both cell lines. Genistein did seem 
to have an effect in this case, with the phospho-AKT expression decreasing in both 
cell lines with the addition of genistein to the 10 minute tunicamycin treated samples 
(lanes 6, 16: T10+) as opposed to the 10 minute tunicamycin treated samples without 
genistein (lanes 5,15: T10-). The effect was more pronounced in the HeLa cells as the 
peak of phospho-AKT at 10 minutes was higher than in the HT1080 cells and hence 
the subsequent decrease in signal with genistein was larger. Aside from the 10 
minute tunicamycin treated samples, the phospho-AKT bands did not seem to 
appear, precluding further analysis.  
To further understand the role of MAPK kinases in the cellular response to ER stress, 
the HT1080 cells and HeLa cells were serum starved and treated with or without 
tunicamycin (Figure 3.1.9). The process of serum starving was used to induce cell 
cycle arrest, which may lead to increased sensitivity to tunicamycin treatment as well 
as controlling for possible unknown effectors of the MAPK pathway contained in the 
FBS. The first point of interest from this data comes from the untreated samples from 
both cell lines. The untreated samples from this experiment (lanes 1,2 and 7,8) were 
dissimilar to the MAPK and phospho-P44/P42 expression seen in the untreated 
samples from the previous experiment (lanes 1,2 and 11,12). All of the PDGFR 
pathway blots exhibited reproducible results for the treated cells, but the first 
experiment shows inconsistency with mock treated cells. Subsequent experiments 









































































































































































































It is possible that the HT1080 cells showed a similar expression of phospho-p44/42 
MAPK to the previous experiment (which used cells grown in media containing 8% 
FBS); however, the HeLa cells exhibited a noticeably lower expression in these bands 
than previously. Aside from the untreated samples, the phospho-P44/P42 expression 
profile is similar to what was observed previously, with a clear peak occurring in the 
10 minute tunicamycin treatment for both cell lines with a subsequent dip in 
expression for the 6 hour tunicamycin treated samples. The 6 hour tunicamycin 
treatment resulted in a relatively low expression of phospho-p44/42 MAPK for the 
HeLa cells, and a slightly higher expression for the HT1080 cells. Serum starving the 
cells seemed to have a clear effect on the HeLa cells, specifically with the 10 minute 
tunicamycin treatment and at the 6 hour timepoint. Strangely, this showed the 
converse of what was expected, with a pronounced reduction in activation of the 
phospho-P44/P42 expression in the 10 minute tunicamycin treated, serum starved 
HeLa cells (compare lanes 3 to 4). The difference that serum starving makes to 
phospho-p44/42 MAPK expression in HT1080 cells is not pronounced, however there 
does still seem to be a minor decrease in expression in the 10 minute tunicamycin 
serum starved lane (compare lanes 9 to 10). The eIF4E loading controls indicated 
even loading. The phospho-AKT bands were very faint in these blots however there 
does seem to be a slight increase in phospho-AKT expression in the non-serum 
starved 10 minute tunicamycin lanes for both cell lines; more so in the HeLa cells, 
which was also the case in the previous experiment.  
The Coomassie brilliant blue stain of the gels containing serum starved lysates (Figure 
3.1.10) acted as a control for lysis and sample recovery. One distinct ~50 kDa band 
was absent in all the serum starved lysates, and this band is likely to be residual 
albumin. 
After seeing the discrepancy of phospho-p44/42 MAPK expression between the 
untreated samples in different experiments on the same gel, lysates from both sets 
of MAPK experiments were loaded next to each other to observe whether 
phosphorylation patterns differed within what should be the same treatments 
(Figure 3.1.11). The genistein and serum starved treatments were excluded, and just 



















































































































































































































































































































































































































Both cell lines having the older (genistein experiment) and newer (serum starved 
experiment) samples loaded next to each other for each treatment. The results show 
that between the experiments, the phosphorylated p44/42 is weak but consistent 
apart from the HT1080 untreated samples where the MAPK and phospho-P44/P42 
expression is clearly stronger in the newer sample generated for the second 
experiment. The 10 minute tunicamycin exhibited the clear peak of phospho-p44/42 
MAPK expression here which demonstrates that across all experiments, there is an 
early, reproducible and almost immediate effect of tunicamycin on MAPK pathways. 
The subsequent dips in expression are the same, with the HeLa cells showing a very 
weak signal in the 6 hour tunicamycin treatment compared to the 10-minute 
treatment. The HT1080 cells again show a dip in expression in the 6 hour tunicamycin 
but it is stronger than the expression in the HeLa cells.  
3.2 Live cell imaging of cells subjected to ER stress 
3.2.1 The effect of tunicamycin on the motility of HeLa and HT1080 cells 
In order to assess the effect that tunicamycin had on the morphology and the motility 
of the two cell lines (HT1080 and HeLa), a series of live cell imaging studies were 
performed. Using a spinning disc microscope allowed motility assays to be performed 
on the cells, but also provided useful qualitative information about how the cells 
responded to the treatments in general. In these experiments, HT1080 cell and HeLa 
cells were either mock treated, tunicamycin treated (1 µg ml-1), genistein treated 
(140 µM) or a combination of genistein and tunicamycin treated to assess whether 
genistein either potentiated or reduced the effect of tunicamycin. The cells were 
then stained with ER tracker blue-white DPX which enabled visualisation of the 
endoplasmic reticulum. The cells were then imaged using the Andor Spinning Disc 
microscope for 6 hours with an image of the cells being taken every minute to create 
a time-lapse movie of 360 frames. The data was then analysed using image J and the 
Mtrack2 plugin was used to track each individual cell’s movement. In multiple 
conditions, some cells disappeared from the field of view and therefore these were 
excluded from analysis as they may skew the results due to truncated measurements. 
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Panels from typical microscope images are shown in Figures 3.2.1 to 3.2.4. Figure 
3.2.1 shows the mock and tunicamycin treated HeLa cells. The beginning of the 6 
hour imaging session for the mock treated HeLa cells is shown in panel A of Figure 
3.2.1, and the morphology of the endoplasmic reticulum appeared varied, however 
in each cell the ER was mainly perinuclear. After 6 hours of mock treatment (Figure 
3.2.1B), the cell tracking lines suggest that each cell has moved a considerable 
distance; with an average distance travelled of 0.139 µm, with the direction of 
migration appearing random. The majority of tunicamycin treated HeLa cells appear 
morphologically normal at the beginning of the 6-hour measurement (Figure 3.2.1C), 
apart from cell number 7, for example, which seems to have an enlarged ER with 
what could be described as a bubbly appearance. After the 6 hours of tunicamycin 
treatment (Figure 3.2.1D), it is evident that multiple cells have migrated much less in 
comparison to the 6 hours of mock treatment, with an average distance of 0.0676 
µm. Figure 3.2.2 shows the genistein and the tunicamycin + genistein treated HeLa 
cells. Figure 3.2.2A shows the genistein treated HeLa cells at the beginning of the 6-
hour treatment, and the morphology of the ER seems similar to the mock treated 
HeLa cells; with clear ER staining. Figure 3.2.2B shows the HeLa cells after 6 hours of 
genistein treatment. While the staining was faded (likely due to photobleaching), the 
morphology still seemed normal, and the migration of the cells appears to be high 
with an average distance of 0.109 µm. The first frame of the genistein + tunicamycin 
treated cells is shown in Figure 3.2.2C, and there were a few cells with shrunken ERs 
compared to the previous conditions (cells 15,14,2). After 6 hours of the genistein + 
tunicamycin treatment (Figure 3.2.2D), the migration did not appear to be noticeably 
lower than the genistein treated HeLa cells, with mean migration distances of 
0.065896552 µm and 0.051852941 µm respectively. Due to photobleaching, it is 
difficult to comment on the comparative morphology here. 
Figure 3.2.3 shows the mock and tunicamycin treated HT1080 cells, and the mock 
cells at the first frame (Figure 3.2.3A) seem very similar morphologically to the HeLa 
cells. In terms of migration, the HT1080 cells did not seem to have migrated as much 
as the HeLa cells after 6 hours of mock treatment, with an average distance of 0.0958 
µm (Figure 3.2.3B). The tunicamycin treated HT1080 cells do not show any 
69 
 
differences in morphology at the beginning (Figure 3.2.3C) and were photobleached 
considerably after 6 hours (Figure 3.2.3D). It is noticeable here that the cells migrated 
a lot after 6 hours, with an average distance of 0.189 µm, and have travelled in more 
extended distances compared to the mock HT1080 cells which moved in a more 
restricted area despite being seeded at a similar density. The genistein and genistein 
+ tunicamycin treated HT1080 cells are shown in Figure 3.2.4, and Figure 3.2.4A 
shows the genistein treated HT1080 cells at the beginning of the 6-hour treatment. 
The morphology here was very similar to the both the HeLa cells and the HT1080 cells 
analysed at the start of other treatments, as expected.  After 6 hours of genistein 
treatment (Figure 3.2.4B), the HT1080 cells did not appear noticeably affected in 
terms of migration with mean migration distances of 0.073961538 µm and  
0.074821429 µm for 6 hour mock and 6 hour mock with genistein respectively. The 
morphology of the genistein + tunicamycin treated HT1080 cells at the first frame 
(Figure 3.2.4C) was not different. After 6 hours of genistein + tunicamycin treatment, 
the cells’ migration was not inhibited with a mean migration of 0.06562069 µm.  
3.2.2 Statistical analysis shows that HeLa cells are sensitive to motility inhibition 
after treatment with tunicamycin. 
 The different ER stress treatments had visible effects on the behaviour of the cells 
but the magnitude of the effect differed between the two cell lines. HeLa cells were 
much more sensitive to the addition of tunicamycin, resulting in a visible reduction 
of movement which was quantitatively demonstrated through the significantly 
reduced movement seen in the tunicamycin treated HeLa cells in comparison with 
the mock condition (Figure 3.2.1,3.2.5 and Table 3.2.1), with the mock treated HeLa 













Figure 3.2.1: Live cell imaging of HeLa cells shows that tunicamycin treatment decreases 
motility. 
Live cell imaging pictures taken of mock treated (A,B) and tunicamycin treated (C,D) HeLa cells 
all stained with ER tracker dye DPX. Panels A and C represent the first frame taken from the 6 
hour time-lapse movie of the cells. Panels B and D represent the last frame from the 6 hour 
time-lapse movie. The coloured lines and dots represent the tracking of individual cells. 
Tunicamycin treatment = 1 µg/ml. While the laser power remained consistent between 
conditions, photo-bleaching can be observed in panel B and this may be because of inefficient 
washing, meaning more residual dye in the media, resulting in the noisier image. In the future, 













Figure 3.2.2: Live cell imaging of HeLa cells shows that genistein does not appear to affect 
motility when combined with tunicamycin. 
Live cell imaging pictures taken of genistein treated (A,B) and tunicamycin + genistein treated 
(C,D) HeLa cells all stained with ER tracker dye DPX. Panels A and C represent the first frame 
taken from the 6 hour time-lapse movie of the cells. Panels B and D represent the last frame 
from the 6 hour time-lapse movie. The coloured lines and dots represent the tracking of 












Figure 3.2.3: Live cell imaging of HT1080 cells shows that tunicamycin treatment seems to 
increase motility. 
Live cell imaging pictures taken of mock treated (A,B) and tunicamycin treated (C,D) HT108 cells 
all stained with ER tracker dye DPX. Panels A and C represent the first frame taken from the 6 
hour time-lapse movie of the cells. Panels B and D represent the last frame from the 6 hour 
time-lapse movie. The coloured lines and dots represent the tracking of individual cells. 














Figure 3.2.4: Live cell imaging of HT1080 cells shows that genistein does not appear to affect 
motility when combined with tunicamycin. 
Live cell imaging pictures taken of genistein treated (A,B) and tunicamycin + genistein treated 
(C,D) HT1080 cells all stained with ER tracker dye DPX. Panels A and C represent the first frame 
taken from the 6 hour time-lapse movie of the cells. Panels B and D represent the last frame 
from the 6 hour time-lapse movie. The coloured lines and dots represent the tracking of 
individual cells. Tunicamycin treatment = 1µg/ml, Genistein treatment = 140 µM 
74 
 
The response of HeLa cells to the treatments was reproducible in repeat experiments 
(microscopy images not shown, Figure 3.2.5), with the mock (untreated) HeLa cells 
exhibiting the highest level of motility and the most noticeable difference being 
between the untreated and the tunicamycin treated cells. Overall, the genistein 
treatment on its own did appear to inhibit migration significantly (Table 3.2.1) – with 
an average motility reduction of 0.0483 µm, but the error bar for the combined result 
is quite high, as in the individual experiments it was not as clear cut. The genistein + 
tunicamycin condition resulted in a marginally lower motility than the genistein 
treatment only in both HeLa experiments, however the average motility is still slightly 
higher than that of the tunicamycin on its own in both experiments. There was an 
example in the genistein + tunicamycin treatment of the HeLa cells where the cells 
appeared to be shrinking drastically and blebbing (Figure 3.2.2C,D). This could be 
indicative of possible apoptosis, although this cannot be concluded with certainty 
without direct analysis of apoptotic markers.  
The HT1080 cells on the other hand were more variable (Figure 3.2.3,3.2.4,3.2.6 and 
Table 3.2.2). The tunicamycin treated HT1080 cells elicited a strong and significant 
increase in motility in the first experiment with an average increase of 0.0936 µm, 
but only a slight increase in the repeat, with an average increase of 0.00525 µm. In 
fact the repeat had no significant changes between the treatments. On one hand this 
does show that tunicamycin did not decrease motility in the HT1080 cells and 
confirms that HeLa and HT1080 cells respond differently to tunicamycin induced ER 
stress. The genistein treated HT1080 cells showed no significant change in motility 
compared to the mock treatment in either experiment, however the genistein + 
tunicamycin treated cells exhibited a significant decrease in motility compared to the 
tunicamycin treatment on its own, suggesting that genistein rescues the effect of 
tunicamycin. The combined data indicates that tunicamycin significantly increased 
migration in the HT1080 cells, however the error bar is very wide indicating a lot of 
variability. It is clear though that tunicamycin does not inhibit migration in the 








Figure 3.2.5: Graphs showing the migration of HeLa cells shows that tunicamycin inhibits 
migration in this cell line. 
 Graphs from the two live cell imaging experiments (1,2) with the combined data  
(combined) showing the mean distance (µm) travelled by HeLa cells under the different 
treatments: Mock = untreated, Tun = 1 µg/ml tunicamycin, Gen = 140 µM genistein. 








Figure 3.2.6: Graphs showing the migration of HT1080 cells shows that tunicamycin does 
not inhibit migration in this cell line. 
 Graphs from the two live cell imaging experiments (1,2) with the combined data  
(combined) showing the mean distance (µm) travelled by HT1080 cells under the different 
treatments: Mock = untreated, Tun = 1 µg/ml tunicamycin, Gen = 140 µM genistein. 
Standard deviation is shown in the error bars 
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Table 3.2.1: Statistical analysis reveals that tunicamycin significantly decreases migration 
in HeLa cells.  
Tukey’s test (parametric) table showing all comparisons between treatments for the HeLa 
live cell imaging experiments and the combined results. 
 
Compared Treatments (1) Significance Mean Difference 
Mock vs. Tunicamycin *** 0.07109 
Mock vs. Genistein ns 0.02949 
Mock vs. Genistein Tun ** 0.05053 
Tunicamycin vs. Genistein ns -0.0416 
Tunicamycin vs. Genistein Tun ns -0.02057 
Genistein vs. Genistein Tun ns 0.02103 
Compared Treatments (2) Significance Mean Difference 
Mock vs. Tunicamycin **** 0.05783 
Mock vs. Genistein **** 0.04359 
Mock vs. Genistein Tun **** 0.05465 
Tunicamycin vs. Genistein ns -0.01424 
Tunicamycin vs. Genistein Tun ns -0.003179 
Genistein vs. Genistein Tun ns 0.01106 
Compared Treatments 
(Combined) 
Significance Mean Difference 
Mock vs. Tunicamycin *** 0.06833 
Mock vs. Genistein *** 0.04680 
Mock vs. Genistein Tun *** 0.06084 
Tunicamycin vs. Genistein ns -0.02154 
Tunicamycin vs. Genistein Tun ns -0.007493 
Genistein vs. Genistein Tun ns 0.01404 
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Table 3.2.2: Statistical analysis reveals that tunicamycin does not inhibit migration in 
HT1080 cells.  
Tukey’s test (parametric) table showing all comparisons between treatments for the 
HT1080 live cell imaging experiments and the combined results. 
 
Compared Treatments (1) Significance Mean Difference 
Mock vs. Tunicamycin **** -0.09356 
Mock vs. Genistein ns 0.005769 
Mock vs. Genistein Tun ns 0.0325 
Tunicamycin vs. Genistein **** 0.09933 
Tunicamycin vs. Genistein Tun **** 0.1261 
Genistein vs. Genistein Tun ns 0.02673 
Compared Treatments (2) Significance Mean Difference 
Mock vs. Tunicamycin ns -0.005246 
Mock vs. Genistein ns -0.01128 
Mock vs. Genistein Tun ns -0.01599 
Tunicamycin vs. Genistein ns -0.006038 
Tunicamycin vs. Genistein Tun ns -0.01074 
Genistein vs. Genistein Tun ns -0.004705 
Compared Treatments 
(Combined) 
Significance Mean Difference 
Mock vs. Tunicamycin ** -0.04593 
Mock vs. Genistein ns -0.0008599 
Mock vs. Genistein Tun ns 0.008341 
Tunicamycin vs. Genistein ** 0.04507 
Tunicamycin vs. Genistein Tun *** 0.05427 
Genistein vs. Genistein Tun ns 0.009201 
 
ns P > 0.05 
* P ≤ 0.05 
** P ≤ 0.01 
*** P ≤ 0.001 
**** 




Within the first experiment on the HT1080 cells there is no observable apoptosis of 
cells in the areas viewed, however in the repeats, the genistein + tunicamycin does 
seem to show some cells shrinking and blebbing. This could indicate the effect of 
genistein ‘rescuing’ ER stress in the cells; removing the barrier to the stress, and 
allowing a typical stress reaction to occur which may lead to apoptosis, due to the 
mechanisms of genistein mentioned earlier in the introduction. It is clear however 
from these live cell imaging experiments that HeLa cells and HT1080 cells have a 
different response to tunicamycin induced stress, with inhibition of motility occurring 
within HeLa cells, indicating sensitivity to tunicamycin, whereas the HT1080 cells did 









































4.1 Discussion overview 
The aim of this project was to investigate differences between two human cell lines, 
HeLa cells and HT1080 cells, in their responses to pharmacological or chemically 
induced stress. This was investigated in combination with the effect of the tyrosine 
kinase inhibitor genistein, which previously showed promise in modulating ER stress.  
4.2 Differential protein expression as a result of pharmacologically 
induced ER stress in HT1080 and HeLa cells.  
4.2.1 The effect of ER stress on the expression of heat shock proteins and 
glycosylation in HT1080 cells and HeLa cells.  
The western blot experiments for expression of GRP94 and HC10 (Figure 3.1.1, Figure 
3.1.3 and Figure 3.1.5) were undertaken to investigate whether the protein pool of 
heat shock proteins changes as a result of chemically induced ER stress, and whether 
ER stress affects the expression or glycosylation of MHC class I molecules. GRP94 is 
known to be upregulated under ER stress (Marzec et al., 2012, p. 94), and for the 
experiments here it was intended for use as an ER stress indicator. Previous findings 
have demonstrated that MHC class I plasma membrane expression on the cell surface 
is significantly decreased when the cells are exposed to chemically induced stress 
from both tunicamycin and thapsigargin (Ulianich et al., 2011). This was also shown 
in a previous study, but the decreased surface expression was induced by palmitate 
instead (Granados et al., 2009). This study also indicated that the overall intracellular 
protein levels of MHC class I were not altered with the induction of ER stress. It would 
seem from these papers that the processing of MHC class I proteins is perturbed but 
the expression remains unaffected. The experiment undertaken for this thesis 
investigated whether the overall expression would differ according to cell type, and 
while it does not measure surface expression, observing any change in glycosylation 
could indicate impaired processing.  
The GRP94 showed a clearer result in Figure 3.1.5 compared to Figure 3.1.1, after 
using lysates with multiple tunicamycin treatment time points and in combination 
with genistein. With this result, the HT1080 cells certainly showed an increase in 
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GRP94 with the tunicamycin treatments, but the HeLa cells less so at the earlier time 
points - at least in the 10 minute tunicamycin treated lysates. The blot showed an 
interesting effect of genistein on GRP94 expression in the HeLa cells, with an increase 
of GRP94 expression when genistein is added in both untreated and 10 minute 
tunicamycin conditions. With DTT and the 10 minute tunicamycin timepoint, the 
GRP94 expression is slightly decreased when genistein is added. Inversely, in the 
HT1080 cells a pronounced reduction of GRP94 expression is seen in the untreated + 
genistein condition, with an increase in expression seen in DTT and 10 minute 
tunicamycin in the presence of genistein. This pattern is the opposite of what is seen 
in the HeLa cells, however in the 30 minute and 6 hour tunicamycin time points, there 
is a reduction of GRP94 expression with genistein which is similar to the HeLa cells. 
The different expression patterns of the stress indicator GRP94 between the cell two 
cell lines highlights cell specific differences in the reaction to genistein. The raised 
expression of GRP94 does point towards activation of stress pathways in both cell 
lines, with an increase in the chaperone GRP94 indirectly indicating an increase in 
ERAD and protein folding. The difference seems to lie in the time point of stress 
activation with the HT1080 cells surprisingly expressing an increase in GRP94 earlier 
than the HeLa cells. The HeLa cells do have a higher expression of GRP94 than the 
HT1080 cells at the 6 hour tunicamycin treatment point. There is a bell-shaped curve 
type stress response with the HT1080 cells, which could explain the potential reason 
a ‘barrier’ to stress was seen by previous research in this lab as it is possible the stress 
response is activated earlier in the cells and earlier time-points are needed to 
highlight this. It could be that the ER stress response decreases to a small extent in 
the HT1080 cells towards the later time points perhaps due to an adaption to the 
stress in the cellular machinery after the initial high response. In the HeLa cells, 
however it is possible that the stress pathways activate more slowly in comparison 
to the HT1080 cells, and instead reach a peak at the 6 hour tunicamycin treatment. 
The use of GRP94 as readout was intended to show differences in UPR induction 
between the cell lines, and although the effect on the overall protein pool were not 
as clear as if RT-PCR analysis of gene expression was used, this still hinted at a 
temporal difference in the activation of stress pathways between the cells.  
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For both cell lines, the initial results indicated a reproducible decrease in the overall 
protein expression in the tunicamycin treated cells when compared to DTT 
treatment. No change in glycosylation was observed however. This result was seen 
at the 6 hour tunicamycin treated timepoint in subsequent experiments suggesting 
that the overall protein pool does decrease after 6 hours of treatment. This longer 
treatment of tunicamycin was not included in the aforementioned paper (Ulianich et 
al., 2011), which had not seen a decrease in overall expression of GRP94 but only 
with a 30 minute tunicamycin treatment. The findings suggest some avenues for 
further exploration, particularly when coupled with previous research produced by 
this laboratory. Looking further into the effects of tunicamycin on glycosylation and 
the expression of MHC class I molecules between cell lines may reveal some 
interesting differences. 
A further test for the ability of tunicamycin blocking glycosylation was performed in 
the blot for PCYOX1 or prenylcysteine oxidase 1 (Figure 3.1.5, bottom panel). 
Prenylcysteine oxidase has three N-glycosylated sites at positions 196, 323 and 353 
(Liu et al., 2005), and therefore disruption of N-glycosylation by tunicamycin could 
be potentially be seen in the western blots. This blot did not show any strong 
differences in glycosylation between timepoints or treatments in either of the cell 
types. A known effect of tunicamycin is the inhibition of N-glycosylation (Esko and 
Bertozzi, 2009), and therefore an expected result would be increased migration due 
to less glycosylation and a lower molecular weight. This was not entirely clear from 
the experiments in this thesis. Therefore, it is possible that the minimal changes seen 
are due to a pre-existing high number of PCYOX glycoproteins, which masks any 
change in glycosylation states for newly synthesised proteins due to a stronger 
expression. These data could indicate that tunicamycin is not effective at blocking 
glycosylation for proteins with longer half lives. 
4.2.2 P-STAT3 - A role for STAT3 in differential ER stress responses? 
The role of STAT3 in the UPR is not entirely clear. There is however evidence of STAT3 
signaling downstream of the PERK UPR branch, via JAK-1 phosphorylation of PERK 
which then goes on to recruit and activate STAT3 via phosphorylation, allowing it to 
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carry out its function as a transcription factor inducing pro-inflammatory cytokines 
including the ER stress linked interleukin 6 (IL6) (Meares et al., 2014). The activation 
of the STAT3 signaling pathway is therefore dependent on PERK (Meares and 
Benveniste, 2013), and this suggests that the presence of STAT3 may useful as an 
indicator of PERK pathway activation, particularly when looking at the 
phosphorylated form. Interestingly one study showed that obesity related ER stress 
inhibited STAT3 phosphorylation in mice hepatocytes (Kimura et al., 2012), by 
comparing the induction of STAT3 phosphorylation by interleukin 6 (IL6) in 
combination +/- tunicamycin. The fact that this was studied in vivo, with tunicamycin 
administered intraperitoneally 8 hours before analysis, and on a different cell type 
may explain the differences between the results seen here, but it is interesting 
nonetheless that tunicamycin induced ER stress seems to inhibit phosphorylation 
induction. It also is notable that tunicamycin appeared to have no effect on STAT3 
phosphorylation when applied on its own in this study either.  
The P-STAT3 (Figure 3.1.7) blot indicates a late tunicamycin induced increase in 
phosphorylated STAT3 with the HeLa cells after 6 hours of tunicamycin treatment. 
The HT1080 cells however show a pre-existing expression of P-STAT3 in the 
untreated samples, which then declined after 10 minutes of tunicamycin treatment, 
and rose again for 30 minutes and 6 hours of tunicamycin treatment. Due to the 
untreated samples exhibiting P-STAT3, it is possible that the phosphorylation of 
STAT3 may not just be reflecting pharmacologically induced ER stress. For example, 
HT1080 cells contain an endogenous N-Ras mutation (Gupta et al., 2000) and Ras 
may be an upstream component of the STAT3 signalling pathway. The activity of Ras 
was shown to be important in the mediation of p38 and JNK signalling in the 
transcriptional activation of STAT3 (Turkson et al., 1999), and therefore if there is a 
mutation causing constitutive activation of Ras in the HT1080 cells, then it is likely 
that the P-STAT3 baseline activity would be raised.  
The STAT3 phosphorylation is a valid reflection of Stat-3 activation and when coupled 
with the inherent mutations in HT1080 cells, it is highly likely that the presence of P-
STAT3 in the untreated HT1080 cells is indicative of constitutive Stat-3 activation. 
However, this activation seems to become lower when exposed to tunicamycin, and 
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rise back up after longer exposures of cells to the drug. Therefore, it is possible that 
with HT1080 cells, stress induction interferes with the constitutive phosphorylation 
of STAT3 via an unknown mechanism. But equally, this could  reflect published data 
on the inhibition of STAT3 phosphorylation seen in mouse hepatocytes treated with 
tunicamycin (Kimura et al., 2012). It is possible that the acute tunicamycin induced 
ER stress inhibits phosphorylation, but chronic tunicamycin induced ER stress 
promotes it. Thus, either by the accumulation of stress or through a restoration of 
the constitutive phosphorylation, the STAT3 becomes active again. Either way, it 
appears that the HT1080 results may not indicate ER stress alone, and this 
consideration means that further study would be needed to differentiate the effects 
of inherent mutations and pharmacological inducers on the presence of P-STAT3, and 
whether there is any synergistic effect between the two.  
The STAT3 results seem to show a consistent pattern of fading of the shadow band – 
STAT3β – at the later timepoints, though this fading occurs more readily in the HeLa 
cells. This lower band at around 75 kDa disappears at the 6 hour tunicamycin 
treatments in both the HeLa cells and HT1080 cells, but is also decreased in the 30 
hour tunicamycin treatments in HeLa cells indicating a possible difference to HT1080 
cells (Figure 3.1.3). A reduction in either isoform of STAT3 may be indirectly indicative 
of phosphorylation. While the upper STAT3α band does not seem to change, a 
reduction in STAT3β expression could show sequestration of the available non-
phosphorylated STAT3β due to a higher amount of phosphorylated Stat-3. If this 
were the case, however, the expected result would most likely show lower STAT3 
expression in both the untreated and 30 minute tunicamycin treated HT1080 
samples, but this is not the case. It is possible that the expression of STAT3 is not 
directly related to the levels of P-STAT3. It is worth noting that in the HeLa cells, there 
is an unusual band consistently expressed at around 150 kDa which currently eludes 
explanation.  




The PDGF-R signalling pathway analysis is particularly interesting due to the patterns 
seen in the phospho-P44/P42 MAPK bands. The p44/42 MAPK (or Erk1/2) can be 
activated downstream of the active Ras-GTP, which activates Raf1 via translocation 
to the plasma membrane from the cytosol (Marais et al., 1995). This then proceeds 
to activate the MEK1 and MEK2 MAPKs which in turn activates the p44/42 MAPKs 
seen in the experiments presented here. The p44/42 MAPKs are translocated to the 
nucleus where they activate a variety of transcription factors through 
phosphorylation. These transcription factors regulate cell growth and proliferation 
(Plattner et al., 1999). These results (Figures 3.1.8, 3.1.9 and 3.1.11) were of interest 
both because of how ER stress may affect the phosphorylation of p44/42 MAPK and 
because of the endogenous N-Ras mutation present in HT1080 cells resulting in 
constitutively active Ras-GTP in the cells (Gupta et al., 2000). The differing effect of 
pharmacologically induced stress between the HT1080 cells and the HeLa cells may 
reveal how this mutation affects the stress related MAPK response. 
The pattern of phosphorylation in the untreated samples across both cell lines was 
unfortunately inconsistent between the different experiments. It seems however 
from Figure 3.1.11, which compares two sample sets, that the HeLa cells exhibit a 
low baseline of phospho-P44/P42 expression in the untreated samples, and the 
HT1080 cells demonstrate a slightly higher expression to start with. Both cell lines 
demonstrate a peak of MAPK activity at the 10 minute tunicamycin treatment, 
however the HeLa cells seem to show a bell-shaped curve, with a tailing off of MAPK 
activity in the 6 hour no genistein tunicamycin treatment. The HT1080 cells on the 
contrary still demonstrate some MAPK activity in the 6 hour tunicamycin treatment, 
suggesting a continuous, unresolved stress response. There is a definite link between 
short term tunicamycin activity and the activation of MAPK p44/42 pathways, with a 
possible attenuation of activity towards the later stages.  
An important pro-survival pathway in cells is PI3K/AKT, which is involved in inhibiting 
apoptosis by promoting stability of the GRP78 protein, especially during endoplasmic 
reticulum induced stress (Dai et al., 2010). Inhibition of this pathway has been shown 
to induce the pro-apoptotic CHOP and promote ER stress induced apoptosis in cells 
(Hyoda et al., 2006; Dai et al., 2010), and therefore it may help indicate what fate the 
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tunicamycin treated cells here will be pushed towards. Both in the HeLa cells and 
HT1080 cells, there is a visible increase of phospho-AKT at the 10 minute tunicamycin 
treatment, and a slight induction at the 6 hour tunicamycin treatment in the HT1080 
cells more so than the HeLa cells. This could be indicative of active pro-survival 
pathways in the cells during these treatment points, suggesting that while there is 
clearly a potent immediate effect of tunicamycin; the cells compensate by AKT 
phosphorylation which in turn promotes GRP78 recruitment to help compensate for 
the stress and keep the cells alive.  
The activation of MAPK is not necessarily an exclusive indicator of ER stress, but it is 
a downstream signalling component in ER stress pathways (Ron and Walter, 2007). 
The activity of MAPK signalling as a consequence of stress in the cell was seen in a 
study by Wei et al. who discovered that mice brain cells under ER stress induced by 
heart failure showed higher levels of phosphorylated p44/42 MAPK, and the 
upregulation of excitatory and inflammatory mediators (Wei et al., 2016a). Enhanced 
ERK (p44/42) activity was found to mediate cyto-protective effects in cells pre-
conditioned with ER stress (Usuki et al., 2013), alongside inhibition of p38/JNK 
pathways. This could suggest that a higher phosphorylation of p44/42 in the HT1080 
cells at the 6 hour timepoint compared to the HeLa cells is indicative of both an 
eventual attenuation of the pro-survival pathways in the HeLa cells, and a continuous 
push towards survival in the HT1080 cells. It is also possible that MAPK signalling – 
while downstream of ER stress – may work as a feed forward mechanism to further 
induce ER stress, possibly through the production of pro-inflammatory cytokines. 
This possible mechanism of MAPK signalling was discovered through the observation 
that ER stress is decreased when MAPK signalling is inhibited (Wei et al., 2016b). This 
may add credence to the possibility that treated HT1080 cells are maintained in a 
state of prolonged ER stress, which could be unresolvable due to a consistent push 
towards survival. 
The known induction of p44/42 under ER stress correlates nicely with these results 
(Figures 3.1.8, 3.1.9 and 3.1.11) which clearly indicate a potent effect of the 
pharmacological stress inducer tunicamycin on the activity of p44/42 MAPK, 
therefore indirectly suggesting that the tunicamycin induces ER stress in these cells. 
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Discounting the inconsistent untreated samples, HT1080 cells perhaps have an 
earlier and prolonged signalling response after induced ER stress in comparison with 
the HeLa cells, which is also seen in the P-STAT3 results. It is possible that the HeLa 
cells are more sensitive to induced ER stress than the HT1080 cells, possibly due to a 
pre-existing low level ER stress response active in the HT1080 cells. With the HeLa 
cells showing a decrease in both the phosphorylation p44/42 MAPK at the 6-hour 
mark, but an increase in the phosphorylation of STAT3, it may be that the activation 
of p44/42 MAPK has some consequent effect on the phosphorylation of STAT3. It has 
been detailed that induction of the c-src - p44/42 MAPK cascade leads to 
phosphorylation of STAT3 (Tkach et al., 2013), which provides context to the link 
between the P-STAT3 and MAPK blots. This suggests that when phosphorylation of 
p44/42 MAPK is seen, the phosphorylation of STAT3 may follow, and certainly this 
could concur with the results seen in these blots. Again, with the N-Ras mutation in 
the HT1080 cells, the higher baseline activity of both p44/42 and STAT3 makes 
biological sense when compared to HeLa cells, which carry wild type Ras genes 
(Leblanc et al., 1999).  
Serum containing media is optimal for cell growth however in experimental 
situations, the poorly defined makeup of serum in formats such as foetal bovine 
serum may present unwanted variables (Krämer et al., 2005). Serum contains many 
growth factors and cytokines (Pirkmajer and Chibalin, 2011) that could feasibly 
influence the signalling pathways under scrutiny in cell biology. In addition to this, a 
side effect of serum starvation can be cellular stress responses and apoptosis due to 
a lack of necessary growth factors and cytokines (Pirkmajer and Chibalin, 2011). 
Serum starvation is thus commonly used as a means to induce a form of physiological 
cellular stress (Arrington and Schnellmann, 2008). Serum starvation also helps create 
a more homogenous cell population due to the induced G0/G1 cell cycle stage 
quiescence in the starved cells.  
The serum starvation experiment (Figure 3.1.9) shows an interesting pattern in that 
it seems to decrease the expression of phosphorylated p44/42 MAPK in comparison 
to non-serum starved blots. This is possibly due to the absence of extra growth 
factors that may trigger the MAPK pathway. What it does show is that the induced 
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p44/42 MAPK activation seen in these experiments is attributable to the action of 
tunicamycin and not other cytokines present in the serum that may have affected 
signalling. Due to the untreated serum starved samples still exhibiting less 
phosphorylated p44/42 than the serum starved tunicamycin samples, this does show 
that it is not just serum starved induced stress acting on the cells, and that 
tunicamycin does potentiate p44/p42 activation. Comparing the untreated to the 
untreated serum starved samples in both HeLa cells and HT1080 cells, there may be 
a slight rise in phosphorylated p44/42 MAPK expression which could indicate a small 
increase in cellular stress due to the serum starvation itself.  
4.2.4 Does genistein potentiate ER stress signalling responses.  
In Figure 5, the action of the tyrosine kinase inhibitor genistein on p44/42 activity 
(Figure 3.1.8) is more potent than its action on GRP94 (Figure 3.1.5). With the HeLa 
cells particularly, it appears to induce a higher activity of p44/42 in the 6 hour 
tunicamycin treated timepoint. This could suggest that genistein makes the HeLa 
cells more susceptible to prolonged ER stress. If genistein inhibits GRP78/BiP, then 
an exaggerated stress response would make sense, as an adaptive resolution to the 
stress via increased protein folding is not as readily achievable. Interestingly, the 
HT1080 cells show little cell specific effect of genistein, which was unexpected as it 
was hypothesised that genistein may rescue the HT1080 cells from the continuous 
low level stress response seen in the other experiments (Figure 3.1.7). However, both 
the HT1080 cells and HeLa cells did show a clear effect of genistein on the induction 
of the pro-survival phospho-AKT in the 10 minute tunicamycin timepoint. The 
genistein seemed to decrease the expression of phospho-AKT in the presence of 
tunicamycin which could indicate that the known action of genistein inhibiting GRP78 
could be exerted indirectly via inhibiting the PI3K/AKT pathway, and it is possible that 
the drive towards the apoptotic cell fate is happening here with the genistein.  
4.2.5 Summary  
From the experiments in Figures 3.1.1 to 3.1.11, there are obvious differences in the 
reactions of the two cell lines to pharmacologically induced stress. The STAT3 
activation is interesting due to reflecting a possible constitutive STAT3 
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phosphorylation in HT1080 cells, while still showing a compounding effect of 
tunicamycin on the phosphorylation. In the HeLa cells, a late appearance of P-STAT3 
indicates later activation of stress-related signalling pathways compared to the 
HT1080 cells. The difference may be due to the pre-existing STAT3 phosphorylation 
in HT1080 cells lowering the threshold for further phosphorylation under additional 
stress stimuli. p44/42 may be a precursor for STAT3 activation as aforementioned, 
and this makes sense in conjunction with the P-STAT3 blots as the HT1080 cells show 
a more prolonged expression of phosphorylated p44/42 and they also show a more 
prolonged P-STAT3 activation. The issue with the PathScan blots lies in the untreated 
samples which are inconsistent between different blots. It is possible that this was 
down to human error or biological variability. However, the samples treated with 
tunicamycin show reproducible results and therefore conclusions can still be made. 
It can be concluded that the HeLa cells exhibit a more conventional cellular response 
to stress stimuli, undergoing a gradual increase in ER stress as the timepoints 
progress, with the bell shaped activation of p44/42 MAPK possibly acting as an 
upstream signalling component in the stress response.  
With the HT1080 cells, the stress response is different, with earlier indicators of 
stress existing; possibly indicating a pre-existing low level ER stress response in the 
cells, or simply reflecting the result of the endogenous N-Ras mutation. Tunicamycin 
still affects the HT1080 cells and appears to do so more rapidly than the HeLa cells, 
but from these data it is difficult to conclude if there would be any clinical 
consequences with using tunicamycin as a treatment for different cell types. 
Therefore, the live cell imaging data provides phenotypic context to these results; 
enabling analysis on how the cell behaviour (motility) changes under treatment, and 
whether there are any morphological changes or apoptosis present. 
4.3 The effect of stress on cell movement 
The action of both tunicamycin and genestein on cells was investigated by live cell 
imaging (Figures 3.2.1 to 3.2.4). Whilst there is limited research on the links between 
ER stress and motility, there is certainly an existing link between increased stress and 
decreased cell migration. Activation of ERAD by the UPR results in the formation of 
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ERAD complexes which recognise subsets of misfolded proteins (Kim et al., 2015). 
One such complex consists of the ER-membrane resident ubiquitin ligase Hrd1 
complexing with SEL1L which nucleates this ERAD complex (Mueller et al., 2008). 
Over-expression of SEL1L inhibits cellular migration of human pancreatic cancer cells 
(Cattaneo et al., 2005). This is through induction of the PTEN protein that causes G1 
stage cell cycle arrest and is known to inhibit cell proliferation, growth and motility 
(Kim et al., 2015). If cells are pushed towards an apoptotic phenotype, it makes sense 
that the motility would also decrease in this instance if the cells are dying. Previous 
studies have demonstrated that tunicamycin has an inhibitory effect on migration, 
both in vivo with epithelial sheet movement using organotypic cell cultures (Gipson 
et al., 1984) and in vitro with human airway epithelial cell wound repair (Dorscheid 
et al., 2001). The activation of the IRE1 and ATF6 pathways by tunicamycin also 
appeared to inhibit PDGF-BB induced migration in vascular smooth muscle cells (Yi 
et al., 2012). There is evidently a knock on effect with ER stress and migration but 
this may ultimately depend on the tissue environment in which the stressed cells lie 
(Sáez et al., 2014); as in cancer, ER stress promotes angiogenesis and invasion which 
contrasts somewhat to the discussed effects of tunicamycin.  
4.3.1 Does tunicamycin affect cell motility differentially between HeLa and HT1080 
cells?  
The results seen here were certainly varied between cell types, with the HeLa cells 
showing a consistent change in phenotype when treated with tunicamycin. The 
graphs indicate that for both the repeat and the initial experiment, the tunicamycin 
does indeed inhibit the motility of the cells significantly (as confirmed by the 1 way 
ANOVA T-test). This significant decline in cellular migration fits with the known action 
of tunicamycin, and suggests that the stress response is affecting the behaviour of 
the cells in a way that is expected in vitro. The HT1080 cells however show a different 
pattern with a significant increase in motility seen in the tunicamycin treatment. This 
result is more variable than the HeLa cells however, and could indicate random 
variability in the cell motility when compared with the large replicable decline in 
migration in the HeLa cells. If the combined data is used to summarise and average 
out the data pools then it shows that the decline in motility seen in the mock vs 
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tunicamycin on the HeLa cells has a P value of <0.001 whereas in the HT1080 cells, 
the increase in motility between these two conditions has a P value of <0.01 which is 
significant to a lesser extent. Tunicamycin clearly affects the HeLa cells potently, 
inhibiting their motility, but with the HT1080 cells, the effect is less potent, and the 
trend – if any – is an increase in motility.  
When looking at the action of genistein in conjunction with tunicamycin, the HeLa 
cells do not show any significant difference to the tunicamycin treatment alone. The 
genistein with tunicamycin treatment does show a similar decrease in motility 
compared to the mock, but it is clear that here, genistein does not have a synergistic 
effect with tunicamycin. Interestingly; the genistein on its own vs the mock treatment 
does show a decrease in motility that is significant. This could potentially be due to 
the genistein causing an increased susceptibility of the cell to any natural stress that 
may occur. The HeLa results show a nicely uniform pattern of how both tunicamycin 
and genistein affect the cells. Again though, in the HT1080 cells, the pattern of 
genistein action on the cells is variable, with a difference between the initial 
experiment and the repeat. The first experiment certainly showed a decrease of 
motility in the genistein with tunicamycin treatment when compared to just the 
tunicamycin, but this may be simply due to the possibly anomalous large increase in 
motility seen in the tunicamycin condition. In the second experiment, there is no 
significant difference with the addition of genistein. When looking at the combined 
result for the HT1080 cells, genistein + tunicamycin significantly decreases the 
motility of the cells compared to just the tunicamycin alone. This suggests that 
genistein does rescue the effects of tunicamycin on the HT1080 cells by restoring the 
cell motility to levels comparable with the mock treatment. Also no decrease in 
motility is seen in response to genistein treatment alone when compared to the 
mock.  
Interestingly, the cell specific reactions to genistein here reflects what was seen in 
the earlier blot for GRP94. In the HeLa cells, untreated cells with genistein elicited an 
increase in the expression of the stress marker which reflects the decrease in motility 
seen in the presence of genistein in the HeLa cells (like the decrease in motility seen 
with tunicamycin). However, in the HT1080 cells GRP94 expression was decreased in 
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the untreated cells with genistein; the lower levels of this stress marker in the 
presence of genistein backs up the fact that no change in motility was seen when 
genistein was added to the untreated cells.  
The cell morphology did not change at a gross level during live cell imaging; apart 
from the cells that are undergoing apoptosis. It is important to note that the images 
seen do not visualise the cell membrane however and instead are visualising the 
endoplasmic reticulum, and therefore changes in morphology may still be occurring 
beyond what can be seen in these experiments.  
From these data, the clearest conclusion is that tunicamycin differentially affects 
HeLa cells and HT1080 cells in terms of their motility, with the HeLa cells showing a 
significant decrease in motility with tunicamycin as opposed to HT1080 cells which 
show either an increase in motility, or no change. The genistein itself seems to have 
no clear-cut effect on the motility of the cells, which may be simply because the 
pathways genistein acts upon do not affect motility. However if genistein was 
restoring ER stress and driving the cells towards apoptosis, a further decrease in 
motility would be expected when genistein is combined with tunicamycin. 
4.4 Overall conclusions 
In conclusion, the results here have demonstrated a differential protein expression 
profile between different cell types when subjected to pharmacologically induced 
stress. The P-STAT3 results have clearly shown a higher baseline level of activation in 
the HT1080 cells which is likely due to the N-Ras mutation inherent to this cell line. 
The P-STAT3 expression in the HeLa cells is likely indicative of PERK pathway 
activation in the UPR, but in the HT1080 cells, it may not be as clear cut due to the 
constitutive STAT3 activation. In terms of ER stress seen in the cells, it would appear 
overall that the HT1080 cells exhibit a low level, chronic stress response which may 
be transiently increased by tunicamycin, but ultimately this cell line seems to be 
showing a pro-survival phenotype when looking at the blots in conjunction with the 
live cell imaging. The HeLa cells on the other hand do not seem to exhibit the same 
initial low level stress response. The HeLa cells do seem to show an immediate 
reaction to tunicamycin with the expression of phospho-p44/42 like the HT1080 cells, 
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but ultimately seem to have a less constant and later activated response to the stress 
compared to the HT1080 cells. 
It may ultimately be that the HT1080 cells and HeLa cells both react initially to the 
tunicamycin in the same way, but it is the later response that differs, with other stress 
indicators in the HeLa cells taking longer to appear, compared to the more 
continuous stress in the HT1080 cells. When viewed in conjunction with the live cell 
imaging it becomes clear that the HeLa cells are more sensitive to tunicamycin 
induced ER stress than the HT1080 cells, due to a significant inhibition of HeLa 
motility which may possibly precede apoptosis. This may be because the HT1080 cells 
have inherent mutations (N-Ras) that mean particular stress related pathways are 
already active. Therefore, it is possible that the threshold for ER stress to overwhelm 
the HT1080 cells and push them towards apoptosis instead of survival may be higher 
than the HeLa cells, due to a native stressed cellular environment in the HT1080 cells. 
This may suggest that the higher baseline stress response in the HT1080 cells results 
in irremediable stress that cannot be conventionally dealt with. The HeLa cells show 
increased sensitivity to stress, the effects of which are only evident towards the 6 
hour timepoint in the blots, but are clearly evident in the live cell imaging via the 
gradual arrest of cell motility. The effects of genistein are mostly not evident, 
although a particularly interesting point is the decrease in phosphorylated AKT seen 
when genistein is added to the 10 minute tunicamycin treatment. This justifies the 
need for further investigation into how genistein may affect other stress related 
pathways, even if it does not noticeably influence aspects such as cell motility or 
observable apoptosis. Figure 4.1 indicates the temporal differences in the expression 
of the main proteins that indicated reactions to the induced ER stress.  
While the modulation of ER stress via genistein is still unclear; the differential 
reaction of the cells to tunicamycin suggests that therapy for ER stress related 
diseases such as ankylosing spondylitis and specific cancers may require specific 
drugs for different cell types. Inducing ER stress can clearly inhibit migration in HeLa 
cells but the lack of response seen in HT1080 cells may suggest that certain mutations 
can block the traditional response to increasing ER stress by creating an environment 
in the cell and ER that allows unresolvable stress to exist without interfering with 
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important cellular functions involved in disease pathology such as migration which is 










Figure 4.1: Temporal differences in ER stress induced protein expression between HeLa and 
HT1080 cells.  
Flow chart showing how the expression of 4 proteins of interest (GRP94, STAT3, P-STAT3 and 
phospho-p44/42 MAPK) changes after various timed tunicamycin treatments. Initial 
untreated blots shown for comparison. Each change is relative to the previous time point, 
with a box representing no change, an upwards arrow indicating an increase in expression 
and a downwards arrow indicating a decrease in expression.  
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The difference between how the two cell lines react to induced ER stress may seem 
abstract, but it is likely due to the highly complex interlinking of various pathways 
involved in ER stress, and the possibility that mutations in various pathways and 
differing proteomes may also affect the cell behaviour. Figure 4.2 shows the main 
observed consequences of tunicamycin induced ER stress in both HeLa cells and 
HT1080 cells, helping indicate the differences between the cell lines. It is also 
important to consider that these two cells are different cell types; with HT1080 cells 
being isolated from a fibrosarcoma (fibroblasts) and HeLa cells being isolated from a 
cervical adenocarcinoma (epithelial cells) Inherently; fibroblasts have a large and 
highly elaborate endoplasmic reticulum to fit their purpose as major components in 
ECM secretion (Baum and Duffy, 2011). Epithelial cells may also have a large 
endoplasmic reticulum for fat absorption and enzyme secretion (Friedman and 
Cardell, 1977); but perhaps a difference in purpose of the ER in these cell types may 
cause differential re-organisation of the ER when subjected to stress. These two cell 
types are also two very different types of cancer with distinct and different activating 
mutations that may well affect how they respond to stress. 
4.5 Future directions 
There is plenty of scope for further investigation after these results. Primarily, the 
reason behind the differential cellular response to stress needs to be investigated. Is 
this because of the mutations in HT1080 cells, or due to the different functions of 
these cell types? The action of genistein on modulating ER stress needs further 
investigation, and obtaining clean blots for the P-tyrosine expression profile would 
be a starting point. Then looking at more direct stress indicators such as a working 
BiP blot and other phosphorylated proteins involved in the UPR signalling pathways 
such as JNK would flesh out the data, and would demonstrate exactly what pathways 









































































































































































































































































































































































Ali, M.M.U., Bagratuni, T., Davenport, E.L., Nowak, P.R., Silva-Santisteban, M.C., Hardcastle, 
A., McAndrews, C., Rowlands, M.G., Morgan, G.J., Aherne, W., Collins, I., Davies, 
F.E., Pearl, L.H., 2011. Structure of the Ire1 autophosphorylation complex and 
implications for the unfolded protein response. EMBO J. 30, 894–905. 
https://doi.org/10.1038/emboj.2011.18 
Allen, R.L., O’Callaghan, C.A., McMichael, A.J., Bowness, P., 1999. Cutting edge: HLA-B27 
can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J. 
Immunol. Baltim. Md 1950 162, 5045–5048. 
Anfinsen, C.B., 1972. The formation and stabilization of protein structure. Biochem. J. 128, 
737–749. 
Arrington, D.D., Schnellmann, R.G., 2008. Targeting of the molecular chaperone oxygen-
regulated protein 150 (ORP150) to mitochondria and its induction by cellular stress. 
Am. J. Physiol. - Cell Physiol. 294, C641–C650. 
https://doi.org/10.1152/ajpcell.00400.2007 
Auf, G., Jabouille, A., Guérit, S., Pineau, R., Delugin, M., Bouchecareilh, M., Magnin, N., 
Favereaux, A., Maitre, M., Gaiser, T., von Deimling, A., Czabanka, M., Vajkoczy, P., 
Chevet, E., Bikfalvi, A., Moenner, M., 2010. Inositol-requiring enzyme 1alpha is a 
key regulator of angiogenesis and invasion in malignant glioma. Proc. Natl. Acad. 
Sci. U. S. A. 107, 15553–15558. https://doi.org/10.1073/pnas.0914072107 
Back, S.H., Kaufman, R.J., 2012. Endoplasmic Reticulum Stress and Type 2 Diabetes. Annu. 
Rev. Biochem. 81, 767–793. https://doi.org/10.1146/annurev-biochem-072909-
095555 
BANERJEE, S., LI, Y., WANG, Z., SARKAR, F.H., 2008. MULTI-TARGETED THERAPY OF CANCER 
BY GENISTEIN. Cancer Lett. 269, 226–242. 
https://doi.org/10.1016/j.canlet.2008.03.052 
Barnstable, C.J., Bodmer, W.F., Brown, G., Galfre, G., Milstein, C., Williams, A.F., Ziegler, A., 
1978. Production of monoclonal antibodies to group A erythrocytes, HLA and other 
human cell surface antigens-new tools for genetic analysis. Cell 14, 9–20. 
Baum, J., Duffy, H.S., 2011. Fibroblasts and Myofibroblasts: What are we talking about? J. 
Cardiovasc. Pharmacol. 57, 376–379. 
https://doi.org/10.1097/FJC.0b013e3182116e39 
BAX BCL2 associated X, apoptosis regulator [Homo sapiens (human)] - Gene - NCBI [WWW 
Document], n.d. URL http://www.ncbi.nlm.nih.gov/gene/581 (accessed 9.6.16). 
Benham, A.M., Cabibbo, A., Fassio, A., Bulleid, N., Sitia, R., Braakman, I., 2000. The CXXCXXC 
motif determines the folding, structure and stability of human Ero1-Lα. EMBO J. 19, 
4493–4502. https://doi.org/10.1093/emboj/19.17.4493 
Blais, J.D., Addison, C.L., Edge, R., Falls, T., Zhao, H., Wary, K., Koumenis, C., Harding, H.P., 
Ron, D., Holcik, M., Bell, J.C., 2006. Perk-dependent translational regulation 
promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. 
Mol. Cell. Biol. 26, 9517–9532. https://doi.org/10.1128/MCB.01145-06 
Bobrovnikova-Marjon, E., Grigoriadou, C., Pytel, D., Zhang, F., Ye, J., Koumenis, C., Cavener, 
D., Diehl, J.A., 2010. PERK promotes cancer cell proliferation and tumor growth by 
limiting oxidative DNA damage. Oncogene 29, 3881–3895. 
https://doi.org/10.1038/onc.2010.153 
Braun, J., Bollow, M., Remlinger, G., Eggens, U., Rudwaleit, M., Distler, A., Sieper, J., 1998. 
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. 
Arthritis Rheum. 41, 58–67. https://doi.org/10.1002/1529-
0131(199801)41:1<58::AID-ART8>3.0.CO;2-G 
Cao, S.S., Kaufman, R.J., 2014. Endoplasmic Reticulum Stress and Oxidative Stress in Cell 




Carrasco, D.R., Sukhdeo, K., Protopopova, M., Sinha, R., Enos, M., Carrasco, D.E., Zheng, M., 
Mani, M., Henderson, J., Pinkus, G.S., Munshi, N., Horner, J., Ivanova, E.V., 
Protopopov, A., Anderson, K.C., Tonon, G., DePinho, R.A., 2007. The Differentiation 
and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis. Cancer 
Cell 11, 349–360. https://doi.org/10.1016/j.ccr.2007.02.015 
Cattaneo, M., Fontanella, E., Canton, C., Delia, D., Biunno, I., 2005. SEL1L Affects Human 
Pancreatic Cancer Cell Cycle and Invasiveness through Modulation of PTEN and 
Genes Related to Cell–Matrix Interactions. Neoplasia N. Y. N 7, 1030–1038. 
Chan, A.T., Kollnberger, S.D., Wedderburn, L.R., Bowness, P., 2005. Expansion and 
enhanced survival of natural killer cells expressing the killer immunoglobulin-like 
receptor KIR3DL2 in spondylarthritis. Arthritis Rheum. 52, 3586–3595. 
https://doi.org/10.1002/art.21395 
Chang, S.-C., Momburg, F., Bhutani, N., Goldberg, A.L., 2005. The ER aminopeptidase, 
ERAP1, trims precursors to lengths of MHC class I peptides by a “molecular ruler” 
mechanism. Proc. Natl. Acad. Sci. U. S. A. 102, 17107–17112. 
https://doi.org/10.1073/pnas.0500721102 
Chen, Y., Brandizzi, F., 2013. IRE1: ER stress sensor and cell fate executor. Trends Cell Biol. 
23. https://doi.org/10.1016/j.tcb.2013.06.005 
Cheriyath, V., Desgranges, Z.P., Roy, A.L., 2002. c-Src-dependent Transcriptional Activation 
of TFII-I. J. Biol. Chem. 277, 22798–22805. 
Chial, H.J., Thompson, H.B., Splittgerber, A.G., 1993. A spectral study of the charge forms of 
Coomassie blue G. Anal. Biochem. 209, 258–266. 
https://doi.org/10.1006/abio.1993.1117 
Clarke, H.J., Chambers, J.E., Liniker, E., Marciniak, S.J., 2014. Endoplasmic Reticulum Stress 
in Malignancy. Cancer Cell 25, 563–573. https://doi.org/10.1016/j.ccr.2014.03.015 
Colbert, R.A., Tran, T.M., Layh-Schmitt, G., 2014. HLA-B27 Misfolding and Ankylosing 
Spondylitis. Mol. Immunol. 57. https://doi.org/10.1016/j.molimm.2013.07.013 
Cortes, A., Pulit, S.L., Leo, P.J., Pointon, J.J., Robinson, P.C., Weisman, M.H., Ward, M., 
Gensler, L.S., Zhou, X., Garchon, H.-J., Chiocchia, G., Nossent, J., Lie, B.A., Førre, Ø., 
Tuomilehto, J., Laiho, K., Bradbury, L.A., Elewaut, D., Burgos-Vargas, R., Stebbings, 
S., Appleton, L., Farrah, C., Lau, J., Haroon, N., Mulero, J., Blanco, F.J., Gonzalez-
Gay, M.A., Lopez-Larrea, C., Bowness, P., Gaffney, K., Gaston, H., Gladman, D.D., 
Rahman, P., Maksymowych, W.P., Crusius, J.B.A., van der Horst-Bruinsma, I.E., 
Valle-Oñate, R., Romero-Sánchez, C., Hansen, I.M., Pimentel-Santos, F.M., Inman, 
R.D., Martin, J., Breban, M., Wordsworth, B.P., Reveille, J.D., Evans, D.M., de 
Bakker, P.I.W., Brown, M.A., 2015. Major histocompatibility complex associations 
of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nat. 
Commun. 6. https://doi.org/10.1038/ncomms8146 
Cullinan, S.B., Diehl, J.A., 2004. PERK-dependent activation of Nrf2 contributes to redox 
homeostasis and cell survival following endoplasmic reticulum stress. J. Biol. Chem. 
279, 20108–20117. https://doi.org/10.1074/jbc.M314219200 
Cullinan, S.B., Zhang, D., Hannink, M., Arvisais, E., Kaufman, R.J., Diehl, J.A., 2003. Nrf2 Is a 
Direct PERK Substrate and Effector of PERK-Dependent Cell Survival. Mol. Cell. Biol. 
23, 7198–7209. https://doi.org/10.1128/MCB.23.20.7198-7209.2003 
Dai, R.Y., Chen, S.K., Yan, D.M., Chen, R., Lui, Y.P., Duan, C.Y., Li, J., He, T., Li, H., 2010. 
PI3K/Akt promotes GRP78 accumulation and inhibits endoplasmic reticulum stress-
induced apoptosis in HEK293 cells. Folia Biol. (Praha) 56, 37–46. 
Dean, L.E., Jones, G.T., MacDonald, A.G., Downham, C., Sturrock, R.D., Macfarlane, G.J., 




Del Porto, P., D’Amato, M., Fiorillo, M.T., Tuosto, L., Piccolella, E., Sorrentino, R., 1994. 
Identification of a novel HLA-B27 subtype by restriction analysis of a cytotoxic 
gamma delta T cell clone. J. Immunol. Baltim. Md 1950 153, 3093–3100. 
Dorscheid, D.R., Wojcik, K.R., Yule, K., White, S.R., 2001. Role of cell surface glycosylation in 
mediating repair of human airway epithelial cell monolayers. Am. J. Physiol. Lung 
Cell. Mol. Physiol. 281, L982-992. 
Eletto, D., Dersh, D., Argon, Y., 2010. GRP94 in ER Quality Control and Stress Responses. 
Semin. Cell Dev. Biol. 21, 479–485. https://doi.org/10.1016/j.semcdb.2010.03.004 
Esko, J.D., Bertozzi, C.R., 2009. Chemical Tools for Inhibiting Glycosylation, in: Varki, A., 
Cummings, R.D., Esko, J.D., Freeze, H.H., Stanley, P., Bertozzi, C.R., Hart, G.W., 
Etzler, M.E. (Eds.), Essentials of Glycobiology. Cold Spring Harbor Laboratory Press, 
Cold Spring Harbor (NY). 
Fedorov, A.N., Baldwin, T.O., 1997. Cotranslational Protein Folding. J. Biol. Chem. 272, 
32715–32718. https://doi.org/10.1074/jbc.272.52.32715 
Friedman, H.I., Cardell, R.R., 1977. Alterations in the endoplasmic reticulum and golgi 
complex of intestinal epithelial cells during fat absorption and after termination of 
this process: A morphological and morphometric study. Anat. Rec. 188, 77–101. 
https://doi.org/10.1002/ar.1091880109 
Galindo, I., Hernáez, B., Muñoz-Moreno, R., Cuesta-Geijo, M.A., Dalmau-Mena, I., Alonso, 
C., 2012. The ATF6 branch of unfolded protein response and apoptosis are 
activated to promote African swine fever virus infection. Cell Death Dis. 3, e341. 
https://doi.org/10.1038/cddis.2012.81 
Gipson, I.K., Kiorpes, T.C., Brennan, S.J., 1984. Epithelial sheet movement: effects of 
tunicamycin on migration and glycoprotein synthesis. Dev. Biol. 101, 212–220. 
Gogada, R., Yadav, N., Liu, J., Tang, S., Zhang, D., Schneider, A., Seshadri, A., Sun, L., Aldaz, 
C.M., Tang, D., Chandra, D., 2012. BIM, a proapoptotic protein, upregulated via 
transcription factor E2F1-dependent mechanism, functions as a prosurvival 
molecule in cancer. J. Biol. Chem. jbc.M112.386102. 
https://doi.org/10.1074/jbc.M112.386102 
Gorman, J.D., Sack, K.E., Davis, J.C., 2002. Treatment of Ankylosing Spondylitis by Inhibition 
of Tumor Necrosis Factor α. N. Engl. J. Med. 346, 1349–1356. 
https://doi.org/10.1056/NEJMoa012664 
Granados, D.P., Tanguay, P.-L., Hardy, M.-P., Caron, É., de Verteuil, D., Meloche, S., 
Perreault, C., 2009. ER stress affects processing of MHC class I-associated peptides. 
BMC Immunol. 10, 10. https://doi.org/10.1186/1471-2172-10-10 
Gupta, S., Plattner, R., Der, C.J., Stanbridge, E.J., 2000. Dissection of Ras-dependent 
signaling pathways controlling aggressive tumor growth of human fibrosarcoma 
cells: evidence for a potential novel pathway. Mol. Cell. Biol. 20, 9294–9306. 
Han, D., Lerner, A.G., Walle, L.V., Upton, J.-P., Xu, W., Hagen, A., Backes, B.J., Oakes, S.A., 
Papa, F.R., 2009. IRE1α Kinase Activation Modes Control Alternate 
Endoribonuclease Outputs to Determine Divergent Cell Fates. Cell 138, 562–575. 
https://doi.org/10.1016/j.cell.2009.07.017 
Han, J., Back, S.H., Hur, J., Lin, Y.-H., Gildersleeve, R., Shan, J., Yuan, C.L., Krokowski, D., 
Wang, S., Hatzoglou, M., Kilberg, M.S., Sartor, M.A., Kaufman, R.J., 2013. ER-stress-
induced transcriptional regulation increases protein synthesis leading to cell death. 
Nat. Cell Biol. 15, 481–490. https://doi.org/10.1038/ncb2738 
Harding, H.P., Novoa, I., Zhang, Y., Zeng, H., Wek, R., Schapira, M., Ron, D., 2000. Regulated 
Translation Initiation Controls Stress-Induced Gene Expression in Mammalian Cells. 
Mol. Cell 6, 1099–1108. https://doi.org/10.1016/S1097-2765(00)00108-8 
103 
 
HAYAKAWA, R., HAYAKAWA, T., TAKEDA, K., ICHIJO, H., 2012. Therapeutic targets in the 
ASK1-dependent stress signaling pathways. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 
88, 434–453. https://doi.org/10.2183/pjab.88.434 
He, C.H., Gong, P., Hu, B., Stewart, D., Choi, M.E., Choi, A.M.K., Alam, J., 2001. Identification 
of Activating Transcription Factor 4 (ATF4) as an Nrf2-interacting Protein 
IMPLICATION FOR HEME OXYGENASE-1 GENE REGULATION. J. Biol. Chem. 276, 
20858–20865. https://doi.org/10.1074/jbc.M101198200 
Hetz, C., 2012. The unfolded protein response: controlling cell fate decisions under ER 
stress and beyond. Nat. Rev. Mol. Cell Biol. 13, 89–102. 
https://doi.org/10.1038/nrm3270 
Hetz, C., Martinon, F., Rodriguez, D., Glimcher, L.H., 2011. The Unfolded Protein Response: 
Integrating Stress Signals Through the Stress Sensor IRE1α. Physiol. Rev. 91, 1219–
1243. https://doi.org/10.1152/physrev.00001.2011 
Hewitt, E.W., 2003. The MHC class I antigen presentation pathway: strategies for viral 
immune evasion. Immunology 110, 163–169. https://doi.org/10.1046/j.1365-
2567.2003.01738.x 
Hoffmann, J.H., Linke, K., Graf, P.C., Lilie, H., Jakob, U., 2004. Identification of a redox-
regulated chaperone network. EMBO J. 23, 160–168. 
https://doi.org/10.1038/sj.emboj.7600016 
Hong, M., Lin, M., Huang, J., Baumeister, P., Hakre, S., Roy, A.L., Lee, A.S., 2005a. 
Transcriptional Regulation of the Grp78 Promoter by Endoplasmic Reticulum Stress 
ROLE OF TFII-I AND ITS TYROSINE PHOSPHORYLATION. J. Biol. Chem. 280, 16821–
16828. https://doi.org/10.1074/jbc.M413753200 
Hong, M., Lin, M., Huang, J., Baumeister, P., Hakre, S., Roy, A.L., Lee, A.S., 2005b. 
Transcriptional Regulation of the Grp78 Promoter by Endoplasmic Reticulum Stress 
ROLE OF TFII-I AND ITS TYROSINE PHOSPHORYLATION. J. Biol. Chem. 280, 16821–
16828. https://doi.org/10.1074/jbc.M413753200 
Hotamisligil, G.S., 2010. Endoplasmic Reticulum Stress and the Inflammatory Basis of 
Metabolic Disease. Cell 140, 900–917. https://doi.org/10.1016/j.cell.2010.02.034 
Huang, Y., Qiu, J., Dong, S., Redell, M.S., Poli, V., Mancini, M.A., Tweardy, D.J., 2007. Stat3 
isoforms, alpha and beta, demonstrate distinct intracellular dynamics with 
prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end. J. 
Biol. Chem. 282, 34958–34967. https://doi.org/10.1074/jbc.M704548200 
Huber, A.-L., Lebeau, J., Guillaumot, P., Pétrilli, V., Malek, M., Chilloux, J., Fauvet, F., Payen, 
L., Kfoury, A., Renno, T., Chevet, E., Manié, S.N., 2013. p58(IPK)-mediated 
attenuation of the proapoptotic PERK-CHOP pathway allows malignant progression 
upon low glucose. Mol. Cell 49, 1049–1059. 
https://doi.org/10.1016/j.molcel.2013.01.009 
Hyoda, K., Hosoi, T., Horie, N., Okuma, Y., Ozawa, K., Nomura, Y., 2006. PI3K-Akt 
inactivation induced CHOP expression in endoplasmic reticulum-stressed cells. 
Biochem. Biophys. Res. Commun. 340, 286–290. 
https://doi.org/10.1016/j.bbrc.2005.12.007 
Iurlaro, R., Muñoz-Pinedo, C., 2016. Cell death induced by endoplasmic reticulum stress. 
FEBS J. 283, 2640–2652. https://doi.org/10.1111/febs.13598 
Kim, H., Bhattacharya, A., Qi, L., 2015. Endoplasmic reticulum quality control in cancer: 
Friend or foe. Semin. Cancer Biol., Theme Series - UPR in Cancer 33, 25–33. 
https://doi.org/10.1016/j.semcancer.2015.02.003 
Kimura, K., Yamada, T., Matsumoto, M., Kido, Y., Hosooka, T., Asahara, S., Matsuda, T., Ota, 
T., Watanabe, H., Sai, Y., Miyamoto, K., Kaneko, S., Kasuga, M., Inoue, H., 2012. 
Endoplasmic Reticulum Stress Inhibits STAT3-Dependent Suppression of Hepatic 
104 
 
Gluconeogenesis via Dephosphorylation and Deacetylation. Diabetes 61, 61–73. 
https://doi.org/10.2337/db10-1684 
Kozaci, L.D., Sari, I., Alacacioglu, A., Akar, S., Akkoc, N., 2009. Evaluation of inflammation 
and oxidative stress in ankylosing spondylitis: a role for macrophage migration 
inhibitory factor. Mod. Rheumatol. 20, 34–39. https://doi.org/10.1007/s10165-
009-0230-9 
Krämer, D.K., Bouzakri, K., Holmqvist, O., Al-Khalili, L., Krook, A., 2005. Effect of serum 
replacement with plysate on cell growth and metabolismin primary cultures of 
human skeletal muscle. Cytotechnology 48, 89–95. 
https://doi.org/10.1007/s10616-005-4074-7 
Lamech, L.T., Haynes, C.M., 2015. The unpredictability of prolonged activation of stress 
response pathways. J. Cell Biol. 209, 781–787. 
https://doi.org/10.1083/jcb.201503107 
Leblanc, V., Delumeau, I., Tocqué, B., 1999. Ras-GTPase activating protein inhibition 
specifically induces apoptosis of tumour cells. Oncogene 18, 4884–4889. 
https://doi.org/10.1038/sj.onc.1202855 
Lee, A.-H., Iwakoshi, N.N., Glimcher, L.H., 2003. XBP-1 Regulates a Subset of Endoplasmic 
Reticulum Resident Chaperone Genes in the Unfolded Protein Response. Mol. Cell. 
Biol. 23, 7448–7459. https://doi.org/10.1128/MCB.23.21.7448-7459.2003 
Lee, A.S., 2005. The ER chaperone and signaling regulator GRP78/BiP as a monitor of 
endoplasmic reticulum stress. Methods San Diego Calif 35, 373–381. 
https://doi.org/10.1016/j.ymeth.2004.10.010 
Lemin, A.J., 2007. Characterisation of the oxidoreductase Erol-Lß and the misfolding of the 
secretory pathway substrate HLA-B27 (Unspecified). Durham University. 
Lemin, A.J., Saleki, K., van Lith, M., Benham, A.M., 2007. Activation of the unfolded protein 
response and alternative splicing of ATF6α in HLA-B27 positive lymphocytes. FEBS 
Lett. 581, 1819–1824. https://doi.org/10.1016/j.febslet.2007.03.069 
Leung-Hagesteijn, C., Erdmann, N., Cheung, G., Keats, J.J., Stewart, A.K., Reece, D.E., Chung, 
K.C., Tiedemann, R.E., 2013. Xbp1s-negative tumor B cells and pre-plasmablasts 
mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer 
Cell 24, 289–304. https://doi.org/10.1016/j.ccr.2013.08.009 
Li, B., Yi, P., Zhang, B., Xu, C., Liu, Q., Pi, Z., Xu, X., Chevet, E., Liu, J., 2011. Differences in 
endoplasmic reticulum stress signalling kinetics determine cell survival outcome 
through activation of MKP-1. Cell. Signal. 23, 35–45. 
https://doi.org/10.1016/j.cellsig.2010.07.019 
Li, X., Zhang, K., Li, Z., 2011. Unfolded protein response in cancer: the Physician’s 
perspective. J. Hematol. Oncol.J Hematol Oncol 4, 8. https://doi.org/10.1186/1756-
8722-4-8 
Lindholm, D., Wootz, H., Korhonen, L., 2006. ER stress and neurodegenerative diseases. Cell 
Death Differ. 13, 385–392. https://doi.org/10.1038/sj.cdd.4401778 
Liu, C.Y., Schröder, M., Kaufman, R.J., 2000. Ligand-independent dimerization activates the 
stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. 
J. Biol. Chem. 275, 24881–24885. https://doi.org/10.1074/jbc.M004454200 
Liu, T., Qian, W.-J., Gritsenko, M.A., Camp, D.G., Monroe, M.E., Moore, R.J., Smith, R.D., 
2005. Human Plasma N-Glycoproteome Analysis by Immunoaffinity Subtraction, 
Hydrazide Chemistry, and Mass Spectrometry. J. Proteome Res. 4, 2070–2080. 
https://doi.org/10.1021/pr0502065 
Marais, R., Light, Y., Paterson, H.F., Marshall, C.J., 1995. Ras recruits Raf-1 to the plasma 
membrane for activation by tyrosine phosphorylation. EMBO J. 14, 3136–3145. 
105 
 
Marzec, M., Eletto, D., Argon, Y., 2012. GRP94: an HSP90-like protein specialized for protein 
folding and quality control in the Endoplasmic Reticulum. Biochim. Biophys. Acta 
1823, 774–787. https://doi.org/10.1016/j.bbamcr.2011.10.013 
Mayer, M.P., Bukau, B., 2005. Hsp70 chaperones: Cellular functions and molecular 
mechanism. Cell. Mol. Life Sci. 62, 670–684. https://doi.org/10.1007/s00018-004-
4464-6 
McCullough, K.D., Martindale, J.L., Klotz, L.O., Aw, T.Y., Holbrook, N.J., 2001. Gadd153 
sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and 
perturbing the cellular redox state. Mol. Cell. Biol. 21, 1249–1259. 
https://doi.org/10.1128/MCB.21.4.1249-1259.2001 
McGonagle, D., 2009. Entheses, enthesitis and enthesopathy. Arthritis Res. UK, Topical 
Reviews. 
Meares, G., Benveniste, E., 2013. ER stress and neuroinflammation: connecting the 
unfolded protein response to JAK/STAT signaling (P5196). J. Immunol. 190, 198.5-
198.5. 
Meares, G.P., Liu, Y., Rajbhandari, R., Qin, H., Nozell, S.E., Mobley, J.A., Corbett, J.A., 
Benveniste, E.N., 2014. PERK-Dependent Activation of JAK1 and STAT3 Contributes 
to Endoplasmic Reticulum Stress-Induced Inflammation. Mol. Cell. Biol. 34, 3911–
3925. https://doi.org/10.1128/MCB.00980-14 
Mueller, B., Klemm, E.J., Spooner, E., Claessen, J.H., Ploegh, H.L., 2008. SEL1L nucleates a 
protein complex required for dislocation of misfolded glycoproteins. Proc. Natl. 
Acad. Sci. 105, 12325–12330. https://doi.org/10.1073/pnas.0805371105 
Nicknam, M.H., Mahmoudi, M., Amirzargar, A.A., Jamshidi, A.R., Rezaei, N., Nikbin, B., 
2009. HLA-B27 subtypes and tumor necrosis factor alpha promoter region 
polymorphism in Iranian patients with ankylosing spondylitis. Eur. Cytokine Netw. 
20, 17–20. https://doi.org/10.1684/ecn.2009.0143 
Oslowski, C.M., Urano, F., 2011. Measuring ER stress and the unfolded protein response 
using mammalian tissue culture system. Methods Enzymol. 490, 71–92. 
https://doi.org/10.1016/B978-0-12-385114-7.00004-0 
Parham, P., Ohta, T., 1996. Population Biology of Antigen Presentation by MHC Class I 
Molecules. Science 272, 67–74. https://doi.org/10.1126/science.272.5258.67 
Parker, R., Phan, T., Baumeister, P., Roy, B., Cheriyath, V., Roy, A.L., Lee, A.S., 2001. 
Identification of TFII-I as the Endoplasmic Reticulum Stress Response Element 
Binding Factor ERSF: Its Autoregulation by Stress and Interaction with ATF6. Mol. 
Cell. Biol. 21, 3220–3233. https://doi.org/10.1128/MCB.21.9.3220-3233.2001 
Paul, M.K., Mukhopadhyay, A.K., 2004. Tyrosine kinase – Role and significance in Cancer. 
Int. J. Med. Sci. 1, 101–115. 
Pierce BCA Protein Assay Kit - Thermo Fisher Scientific [WWW Document], n.d. URL 
https://www.thermofisher.com/order/catalog/product/23225 (accessed 8.2.16). 
Pirkmajer, S., Chibalin, A.V., 2011. Serum starvation: caveat emptor. Am. J. Physiol. - Cell 
Physiol. 301, C272–C279. https://doi.org/10.1152/ajpcell.00091.2011 
Plattner, R., Gupta, S., Khosravi-Far, R., Sato, K.Y., Perucho, M., Der, C.J., Stanbridge, E.J., 
1999. Differential contribution of the ERK and JNK mitogen-activated protein kinase 
cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon 
carcinoma cells. Oncogene 18, 1807–1817. https://doi.org/10.1038/sj.onc.1202482 
Puthalakath, H., O’Reilly, L.A., Gunn, P., Lee, L., Kelly, P.N., Huntington, N.D., Hughes, P.D., 
Michalak, E.M., McKimm-Breschkin, J., Motoyama, N., Gotoh, T., Akira, S., Bouillet, 
P., Strasser, A., 2007. ER stress triggers apoptosis by activating BH3-only protein 
Bim. Cell 129, 1337–1349. https://doi.org/10.1016/j.cell.2007.04.027 
Rawson, R.B., 2002. Regulated intramembrane proteolysis: from the endoplasmic reticulum 
to the nucleus. Essays Biochem. 38, 155–168. 
106 
 
Reimold, A.M., Iwakoshi, N.N., Manis, J., Vallabhajosyula, P., Szomolanyi-Tsuda, E., 
Gravallese, E.M., Friend, D., Grusby, M.J., Alt, F., Glimcher, L.H., 2001. Plasma cell 
differentiation requires the transcription factor XBP-1. Nature 412, 300–307. 
https://doi.org/10.1038/35085509 
Romero-Ramirez, L., Cao, H., Nelson, D., Hammond, E., Lee, A.-H., Yoshida, H., Mori, K., 
Glimcher, L.H., Denko, N.C., Giaccia, A.J., Le, Q.-T., Koong, A.C., 2004. XBP1 is 
essential for survival under hypoxic conditions and is required for tumor growth. 
Cancer Res. 64, 5943–5947. https://doi.org/10.1158/0008-5472.CAN-04-1606 
Ron, D., Walter, P., 2007. Signal integration in the endoplasmic reticulum unfolded protein 
response. Nat. Rev. Mol. Cell Biol. 8, 519–529. https://doi.org/10.1038/nrm2199 
Rutkowski, D.T., Arnold, S.M., Miller, C.N., Wu, J., Li, J., Gunnison, K.M., Mori, K., Sadighi 
Akha, A.A., Raden, D., Kaufman, R.J., 2006. Adaptation to ER stress is mediated by 
differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS 
Biol. 4, e374. https://doi.org/10.1371/journal.pbio.0040374 
Sáez, P.J., Villalobos-Labra, R., Westermeier, F., Sobrevia, L., Farías-Jofré, M., 2014. 
Modulation of endothelial cell migration by ER stress and insulin resistance: a role 
during maternal obesity? Front. Pharmacol. 5. 
https://doi.org/10.3389/fphar.2014.00189 
Sano, R., Reed, J.C., 2013. ER stress-induced cell death mechanisms. Biochim. Biophys. Acta 
BBA - Mol. Cell Res. 1833, 3460–3470. 
https://doi.org/10.1016/j.bbamcr.2013.06.028 
Schittenhelm, R.B., Sian, T.C.C.L.K., Wilmann, P.G., Dudek, N.L., Purcell, A.W., 2015. 
Revisiting the arthritogenic peptide theory: quantitative not qualitative changes in 
the peptide repertoire of HLA-B27 allotypes. Arthritis Rheumatol. Hoboken NJ 67, 
702–713. https://doi.org/10.1002/art.38963 
Seger, R., Krebs, E.G., 1995. The MAPK signaling cascade. FASEB J. Off. Publ. Fed. Am. Soc. 
Exp. Biol. 9, 726–735. 
Shamji, M.F., Bafaquh, M., Tsai, E., 2008. The pathogenesis of ankylosing spondylitis. 
Neurosurg. Focus 24, E3. https://doi.org/10.3171/FOC/2008/24/1/E3 
Shiau, M., Lo, M., Chang, C., Yang, T., Ho, K., Chang, Y., 2007. Association of tumour 
necrosis factor α promoter polymorphisms with ankylosing spondylitis in Taiwan. 
Ann. Rheum. Dis. 66, 562–563. https://doi.org/10.1136/ard.2006.065888 
Sieper, J., Braun, J., Rudwaleit, M., Boonen, A., Zink, A., 2002. Ankylosing spondylitis: an 
overview. Ann. Rheum. Dis. 61, iii8-iii18. 
https://doi.org/10.1136/ard.61.suppl_3.iii8 
Spagnuolo, C., Russo, G.L., Orhan, I.E., Habtemariam, S., Daglia, M., Sureda, A., Nabavi, S.F., 
Devi, K.P., Loizzo, M.R., Tundis, R., Nabavi, S.M., 2015. Genistein and Cancer: 
Current Status, Challenges, and Future Directions. Adv. Nutr. Int. Rev. J. 6, 408–419. 
https://doi.org/10.3945/an.114.008052 
Stam, N.J., Spits, H., Ploegh, H.L., 1986. Monoclonal antibodies raised against denatured 
HLA-B locus heavy chains permit biochemical characterization of certain HLA-C 
locus products. J. Immunol. 137, 2299–2306. 
Stosic-Grujicic, S., Stojanovic, I., Maksimovic-Ivanic, D., Momcilovic, M., Popadic, D., 
Harhaji, L., Miljkovic, D., Metz, C., Mangano, K., Papaccio, G., Al-Abed, Y., Nicoletti, 
F., 2008. Macrophage migration inhibitory factor (MIF) is necessary for progression 
of autoimmune diabetes mellitus. J. Cell. Physiol. 215, 665–675. 
https://doi.org/10.1002/jcp.21346 
Szegezdi, E., Logue, S.E., Gorman, A.M., Samali, A., 2006. Mediators of endoplasmic 




(tasc), T.A.-A.-A.S.C., (wtccc2),  the W.T.C.C.C. 2, Evans, D.M., Spencer, C.C.A., Pointon, J.J., 
Su, Z., Harvey, D., Kochan, G., Oppermann, U., Dilthey, A., Pirinen, M., Stone, M.A., 
Appleton, L., Moutsianas, L., Leslie, S., Wordsworth, T., Kenna, T.J., Karaderi, T., 
Thomas, G.P., Ward, M.M., Weisman, M.H., Farrar, C., Bradbury, L.A., Danoy, P., 
Inman, R.D., Maksymowych, W., Gladman, D., Rahman, P., (sparcc), S.R.C. of C., 
Morgan, A., Marzo-Ortega, H., Bowness, P., Gaffney, K., Gaston, J.S.H., Smith, M., 
Bruges-Armas, J., Couto, A.-R., Sorrentino, R., Paladini, F., Ferreira, M.A., Xu, H., Liu, 
Y., Jiang, L., Lopez-Larrea, C., Díaz-Peña, R., López-Vázquez, A., Zayats, T., Band, G., 
Bellenguez, C., Blackburn, H., Blackwell, J.M., Bramon, E., Bumpstead, S.J., Casas, 
J.P., Corvin, A., Craddock, N., Deloukas, P., Dronov, S., Duncanson, A., Edkins, S., 
Freeman, C., Gillman, M., Gray, E., Gwilliam, R., Hammond, N., Hunt, S.E., 
Jankowski, J., Jayakumar, A., Langford, C., Liddle, J., Markus, H.S., Mathew, C.G., 
McCann, O.T., McCarthy, M.I., Palmer, C.N.A., Peltonen, L., Plomin, R., Potter, S.C., 
Rautanen, A., Ravindrarajah, R., Ricketts, M., Samani, N., Sawcer, S.J., Strange, A., 
Trembath, R.C., Viswanathan, A.C., Waller, M., Weston, P., Whittaker, P., Widaa, S., 
Wood, N.W., McVean, G., Reveille, J.D., Wordsworth, B.P., Brown, M.A., Donnelly, 
P., 2011. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis 
implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. 
Nat. Genet. 43, 761–767. https://doi.org/10.1038/ng.873 
Tkach, M., Rosemblit, C., Rivas, M.A., Proietti, C.J., Flaqué, M.C.D., Mercogliano, M.F., 
Beguelin, W., Maronna, E., Guzmán, P., Gercovich, F.G., Deza, E.G., Elizalde, P.V., 
Schillaci, R., 2013. p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is 
required for progestin-induced full activation of Stat3 and breast cancer growth. 
Endocr. Relat. Cancer 20, 197–212. https://doi.org/10.1530/ERC-12-0194 
Tournier, C., Hess, P., Yang, D.D., Xu, J., Turner, T.K., Nimnual, A., Bar-Sagi, D., Jones, S.N., 
Flavell, R.A., Davis, R.J., 2000. Requirement of JNK for stress-induced activation of 
the cytochrome c-mediated death pathway. Science 288, 870–874. 
Turkson, J., Bowman, T., Adnane, J., Zhang, Y., Djeu, J.Y., Sekharam, M., Frank, D.A., 
Holzman, L.B., Wu, J., Sebti, S., Jove, R., 1999. Requirement for Ras/Rac1-Mediated 
p38 and c-Jun N-Terminal Kinase Signaling in Stat3 Transcriptional Activity  Induced 
by the Src Oncoprotein. Mol. Cell. Biol. 19, 7519–7528. 
Turner, M.J., Delay, M.L., Bai, S., Klenk, E., Colbert, R.A., 2007. HLA-B27 up-regulation 
causes accumulation of misfolded heavy chains and correlates with the magnitude 
of the unfolded protein response in transgenic rats: Implications for the 
pathogenesis of spondylarthritis-like disease. Arthritis Rheum. 56, 215–223. 
https://doi.org/10.1002/art.22295 
Uchio, N., Oma, Y., Toriumi, K., Sasagawa, N., Tanida, I., Fujita, E., Kouroku, Y., Kuroda, R., 
Momoi, T., Ishiura, S., 2007. Endoplasmic reticulum stress caused by aggregate-
prone proteins containing homopolymeric amino acids. FEBS J. 274, 5619–5627. 
https://doi.org/10.1111/j.1742-4658.2007.06085.x 
Ulianich, L., Terrazzano, G., Annunziatella, M., Ruggiero, G., Beguinot, F., Di Jeso, B., 2011. 
ER stress impairs MHC Class I surface expression and increases susceptibility of 
thyroid cells to NK-mediated cytotoxicity. Biochim. Biophys. Acta BBA - Mol. Basis 
Dis. 1812, 431–438. https://doi.org/10.1016/j.bbadis.2010.12.013 
Upton, J.-P., Wang, L., Han, D., Wang, E.S., Huskey, N.E., Lim, L., Truitt, M., McManus, M.T., 
Ruggero, D., Goga, A., Papa, F.R., Oakes, S.A., 2012. IRE1α Cleaves Select 
microRNAs During ER Stress to Derepress Translation of Proapoptotic Caspase-2. 
Science 338, 818–822. https://doi.org/10.1126/science.1226191 
Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H.P., Ron, D., 2000. 
Coupling of stress in the ER to activation of JNK protein kinases by transmembrane 
protein kinase IRE1. Science 287, 664–666. 
108 
 
Urra, H., Dufey, E., Avril, T., Chevet, E., Hetz, C., 2016. Endoplasmic Reticulum Stress and 
the Hallmarks of Cancer. Trends Cancer 2, 252–262. 
https://doi.org/10.1016/j.trecan.2016.03.007 
Usuki, F., Fujimura, M., Yamashita, A., 2013. Endoplasmic reticulum stress preconditioning 
attenuates methylmercury-induced cellular damage by inducing favorable stress 
responses. Sci. Rep. 3, 2346. https://doi.org/10.1038/srep02346 
Vakifahmetoglu-Norberg, H., Zhivotovsky, B., 2010. The unpredictable caspase-2: what can 
it do? Trends Cell Biol. 20, 150–159. https://doi.org/10.1016/j.tcb.2009.12.006 
van der Linden, S.M., Valkenburg, H.A., de Jongh, B.M., Cats, A., 1984. The risk of 
developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of 
relatives of spondylitis patients with the general population. Arthritis Rheum. 27, 
241–249. 
Vidal, R.L., Hetz, C., 2013. Unspliced XBP1 controls autophagy through FoxO1. Cell Res. 23, 
463–464. https://doi.org/10.1038/cr.2013.9 
Wang, M., Kaufman, R.J., 2014. The impact of the endoplasmic reticulum protein-folding 
environment on cancer development. Nat. Rev. Cancer 14, 581–597. 
https://doi.org/10.1038/nrc3800 
Wang, Y., Alam, G.N., Ning, Y., Visioli, F., Dong, Z., Nör, J.E., Polverini, P.J., 2012. The 
unfolded protein response induces the angiogenic switch in human tumor cells 
through the PERK/ATF4 pathway. Cancer Res. 72, 5396–5406. 
https://doi.org/10.1158/0008-5472.CAN-12-0474 
Wei, S.-G., Yu, Y., Weiss, R.M., Felder, R.B., 2016a. Endoplasmic Reticulum (ER) Stress 
Induces p44/42 Mitogen-Activated Protein Kinase (MAPK) Signaling, Inflammation 
and Renin-Angiotensin System (RAS) Activity in Forebrain and Contributes to 
Sympathetic Nerve Activity in Heart Failure Rats. FASEB J. 30, 1005.2-1005.2. 
Wei, S.-G., Yu, Y., Weiss, R.M., Felder, R.B., 2016b. Inhibition of brain mitogen-activated 
protein kinase signaling reduces central endoplasmic reticulum stress and 
inflammation and sympathetic nerve activity in heart failure rats. Hypertension 67, 
229–236. https://doi.org/10.1161/HYPERTENSIONAHA.115.06329 
Wu, A.H., Yu, M.C., Tseng, C.-C., Pike, M.C., 2008. Epidemiology of soy exposures and breast 
cancer risk. Br. J. Cancer 98, 9–14. https://doi.org/10.1038/sj.bjc.6604145 
Yan, L., Spitznagel, E.L., 2009. Soy consumption and prostate cancer risk in men: a revisit of 
a meta-analysis. Am. J. Clin. Nutr. 89, 1155–1163. 
https://doi.org/10.3945/ajcn.2008.27029 
Yi, N., Chen, S.-Y., Ma, A., Chen, P.-S., Yao, B., Liang, T.-M., Liu, C., 2012. Tunicamycin 
inhibits PDGF-BB-induced proliferation and migration of vascular smooth muscle 
cells through induction of HO-1. Anat. Rec. Hoboken NJ 2007 295, 1462–1472. 
https://doi.org/10.1002/ar.22539 
Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., Mori, K., 2001. XBP1 mRNA Is Induced by 
ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active 
Transcription Factor. Cell 107, 881–891. https://doi.org/10.1016/S0092-
8674(01)00611-0 
Zambrano-Zaragoza, J., Francisco, Agraz-Cibrian, J.M., Gonz&#xe1, lez-Reyes, C., Dur&#xe1, 
n-Avelar, M. de J., s, Vibanco-P&#xe9, Rez, N., Zambrano-Zaragoza, J., Francisco, 
Agraz-Cibrian, J.M., Gonz&#xe1, lez-Reyes, C., Dur&#xe1, n-Avelar, M. de J., s, 
Vibanco-P&#xe9, Rez, N., 2013. Ankylosing Spondylitis: From Cells to Genes, 
Ankylosing Spondylitis: From Cells to Genes. Int. J. Inflamm. Int. J. Inflamm. 2013, 
2013, e501653. https://doi.org/10.1155/2013/501653, 10.1155/2013/501653 
Zarubin, T., Han, J., 2005. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 
15, 11–18. https://doi.org/10.1038/sj.cr.7290257 
109 
 
Zhang, K., Kaufman, R.J., 2004. Signaling the Unfolded Protein Response from the 
Endoplasmic Reticulum. J. Biol. Chem. 279, 25935–25938. 
https://doi.org/10.1074/jbc.R400008200 
Zhang, X., Yuan, Y., Jiang, L., Zhang, J., Gao, J., Shen, Z., Zheng, Y., Deng, T., Yan, H., Li, W., 
Hou, W.-W., Lu, J., Shen, Y., Dai, H., Hu, W.-W., Zhang, Z., Chen, Z., 2014. 
Endoplasmic reticulum stress induced by tunicamycin and thapsigargin protects 
against transient ischemic brain injury. Autophagy 10, 1801–1813. 
https://doi.org/10.4161/auto.32136 
Zhou, H.-B., Chen, J.-J., Wang, W.-X., Cai, J.-T., Du, Q., 2004. Apoptosis of human primary 
gastric carcinoma cells induced by genistein. World J. Gastroenterol. WJG 10, 
1822–1825. https://doi.org/10.3748/wjg.v10.i12.1822 
Zhou, Y., Lee, A.S., 1998a. Mechanism for the Suppression of the Mammalian Stress 
Response by Genistein, an Anticancer Phytoestrogen From Soy. J. Natl. Cancer Inst. 
90, 381–388. https://doi.org/10.1093/jnci/90.5.381 
Zhou, Y., Lee, A.S., 1998b. Mechanism for the Suppression of the Mammalian Stress 
Response by Genistein, an Anticancer Phytoestrogen From Soy. JNCI J. Natl. Cancer 
Inst. 90, 381–388. https://doi.org/10.1093/jnci/90.5.381 
Zwanzig, R., Szabo, A., Bagchi, B., 1992. Levinthal’s paradox. Proc. Natl. Acad. Sci. U. S. A. 
89, 20–22. 
 
